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ABSTRACT 
Liposomes are lipid particles formed by self-aggregated phospholipids. They are 
clinically used both as delivery vectors and immune adjuvants to treat many human 
infectious and cancerous diseases. However, how liposomes interact with host immune 
system remains poorly understood. Particularly, little is known about whether an innate 
immune receptor exists to sense liposomes. I hypothesize that liposomes activate NLRP3 
inflammasome in macrophages, which results in the release of interleukin 1β (IL-1β), a 
proinflammatory cytokine that plays a key role in innate and adaptive immune responses. 
To test my hypothesis, I will determine the ability of inducing IL-1β secretion 
from macrophages by differentially charged liposomes (i.e. cationic, neutral or anionc 
liposomes). Furthermore, I will also test whether the intact NLRP3 inflammasome 
machinery is required for liposomes-induced IL-1β secretion.  Notably, similar to 
liposomes, accumulating evidence has indicated that exposure to other particulates, such 
as crystals, can also activate the NLRP3 inflammasome in phagocytes. To delineate the 
molecular mechanism by which particulates (liposomes/crystals) activate the NLRP3 
inflammasome, I further hypothesize that particulates induce oxidative stress in 
macrophages resulting in the production of mitochondrial reactive oxygen species (ROS). 
Accumulation of ROS can then induce calcium influx via the transient receptor potential 
melastatin 2 (TRPM2) ion channel, which results in the drastic increase of intracellular 
calcium concentration. The change in the ionic environment would create a favorable 
 xvi 
condition for activation of the NLRP3 inflammasome. To test this, I plan to use 
combinations of chemical and genetic approaches. First, I will determine whether 
liposomes can induce mitochondrial ROS production and subsequent ROS-dependent 
calcium influx via TRPM2 in vitro. Next, by taking advantage of the TRPM2 gene 
knockout mice, I will further determine if genetic ablation of TRPM2 could impair 
liposomes/crystals-induce NLRP3 inflammasome activation both in vitro and in vivo. 
Lastly, because IL-1β-IL-1 receptor signaling axis is critical for inducing humoral 
immune responses, I want to test if blocking this signaling pathway would affect 
liposomal adjuvant effect in vivo. Briefly, I will determine if, in comparison with wild-
type animals, IL-1RI deficient mice would have any defect in mounting target-antigen 
specific antibody responses. Taken together, this project will not only identify the 
previously unknown innate immune sensor for liposomes, but also provide novel insights 
of the molecular mechanism underlying particle-induced NLRP3 inflammasome 
activation. 
1 
CHAPTER 1 
INTRODUCTION 
LIPOSOMES 
Liposomes are lipid particles that are formed by self-aggregated phospholipids 
(Allison and Gregoriadis, 1974; Christensen et al., 2007; Slingerland et al., 2012). The 
lipids contain a nonpolar portion, typically consisting of fatty acid chains, and a polar 
portion, typically consisting of a phosphate group and/or tertiary ammonium salts(Allison 
and Gregoriadis, 1974; Miller et al., 1998; Perrie et al., 2003; Slingerland et al., 2012; 
Vyas and Khatri, 2007). Based on the different charge of the polar region, liposomes can 
be further subgrouped into positively charged (cationic), negatively charged (anionic) and 
neutral liposomes (Christensen et al., 2007; Perrie et al., 2003; Slingerland et al., 2012; 
Vyas and Khatri, 2007). A large panel of phospholipids can be made into liposomes. 
Liposomes are useful tools that can be clinically used to treat human diseases. They can 
be used as drug delivery vector/vesicle in anti-cancer therapy, and they are also very 
important immune adjuvant because they possess strong immunoactivating properties 
(Allison and Gregoriadis, 1974; Christensen et al., 2007; Slingerland et al., 2012). 
Liposomes are considered as one of the next-generation delivery vectors that are 
superior to many conventional therapeutic vectors for in vivo drug-delivery purpose 
because the composition and structure of liposomes are highly manipulable (Allison and 
Gregoriadis, 1974; Christensen et al., 2007; Slingerland et al., 2012). For instance, certain 
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molecules can be directly incorporated into the lipid-bilayer of liposomes or 
anchored/attached covalently to the lipids(Christensen et al., 2007; Slingerland et al., 
2012; Vyas and Khatri, 2007; Walker et al., 1992). This will maximize the amount of 
drugs carried by delivery vectors and ensure optimal drug efficacy. The ease of attaching 
molecules onto the lipid shell is also helpful for target-cell delivery purpose, especially in 
anti-cancer therapy where cancer cell-directed drug delivery is highly 
desirable(Slingerland et al., 2012). Additionally, in comparison with other next-
generation delivery vectors, such as synthetic polymeric nanoparticles, liposomes can be 
easily made into multilamellar liposome, where multiple layers of lipids within the single 
liposomes can trap more abundant drugs to ensure gradual and constant release of 
therapeutic agents entrapped within each layer.(Zucker et al., 2009) It has been shown 
that utilization of multilamellar liposome can substantially improve the anti-cancer 
therapeutic efficacy(Pagano, 1978; Pagano and Weinstein, 1978; Satish and Surolia, 2002; 
Segota and Tezak, 2006).  
From an immunologic point of view, liposomes are also ideal immune adjuvant 
because they are more potent than the conventional adjuvant, such as alum, at amplifying 
the adaptive immune responses against co-administered antigens(Allison and 
Gregoriadis, 1974; Christensen et al., 2007). Interestingly, it appears that the chemical 
properties of lipids largely determine the immunologic use of liposomes. Particularly, the 
surface charge of liposomes has a major influence on the differential ability to activate 
the immune system(Allison and Gregoriadis, 1974; Christensen et al., 2007). In contrast 
to the neutral ones, charged liposomes (either cationic or anionic liposomes) are more 
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commonly used as immune adjuvants because they seem to possess stronger ability to 
facilitate the optimal induction of antigen-specific immunity. For instance, the DOTAP 
liposomes, DC-Chol liposomes, and DDA liposomes are all ideal immune adjuvants and 
they have been shown to be able to significantly amplify antigen-specific immunity. In 
contrast to charged liposomes, the neutral ones are week adjuvants(Allison and 
Gregoriadis, 1974; Christensen et al., 2007).  
DOTAP liposome is one example of cationic liposomes that can be used as 
immune adjuvants. The co-immunization with target protein/peptide with DOTAP 
liposomes can elicit CD8+ T cell responses with increased cytolytic T cell activity(Cui et 
al., 2005; Walker et al., 1992). Previous studies have suggested that treatment of DOTAP 
liposomes can upregulate co-stimulatory molecules (e.g. CD80/86) in antigen presenting 
cells to facilitate innate immune cell maturation(Satish and Surolia, 2002; Vangasseri et 
al., 2006). Moreover, DOTAP liposomes are also capable of activating MAPK in 
dendritic cells (DCs), which might play a role in directing downstream cytokine and 
chemokine expression(Yan et al., 2007).  
DC-Chol liposomes are another type of cationic liposomes that can generate a 
balanced Th1/Th2 response in several animal models(Brunel et al., 1999; Gao and 
Huang, 1991; Sanchez et al., 2001). It has been shown that the antibody responses against 
human inactivated influenza vaccine can be enhanced if DC-Chol liposomes were 
formulated into the vaccine(Guy et al., 2001). DC-Chol liposomes are also effective 
mucosal adjuvant and were able to upregulate CCL20 expression in epithelial cells from 
both vagina and uterus(Hattori et al., 2004). Furthermore, the combination of DC-Chol 
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liposomes with TLR ligands (such as zymosan, a TLR2 agonist) has been shown to 
induce maturation of DCs and Langerhans’ cells(Cremel et al., 2006).  
DDA is another cationic lipid that can form liposomes when heated to above its 
gel-liquid phase transition temperature (470C)(Davidsen et al., 2005; Feitosa et al., 2000). 
It has been shown that immunization of mice with hapten-carrier complexes and DDA 
liposomes generated hapten-specific delayed-hypersensitivity, suggesting the DDA 
liposomes are able to induce a cell-mediated immunity(Dailey and Hunter, 1974; Snippe 
et al., 1977). Furthermore, DDA liposomes have also been used as immune adjuvant in 
various vaccine formulations against viruses, bacteria and even tumors(Katz et al., 1996; 
Klinguer-Hamour et al., 2002; Kraaijeveld et al., 1983; Lindblad et al., 1997; Prager and 
Gordon, 1978). Notably, DDA has been shown to be a safe immune adjuvant that does 
not appear to have side effect as seen by other immune adjuvants in humans(Hilgers and 
Snippe, 1992; Stanfield et al., 1973; Veronesi et al., 1970).  
Although certain charged liposomes are strong immune adjuvants themselves, 
they can also be used in combination with other immumodulators, such as pathogen-
associated molecular patterns (PAMPs) molecules (e.g. TLR agonists) or self danger-
associated molecular patterns (DAMPs) molecules (e.g. HMGB1, dsRNA, 
ATP)(Christensen et al., 2007). It has been shown that such combinational approaches 
can further enhance the adjuvanticity of charged liposomes and be helpful at inducing a 
desirable Th1/Th2 biased or balanced immune responses, respectively(Christensen et al., 
2007; Klinguer-Hamour et al., 2002; Pagano, 1978).  
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In summary, liposomes are both efficient drug-delivery vectors and powerful 
immune adjuvants. Their clinical use has been proven to be beneficial for the treatment of 
many human infectious and cancerous diseases(Allison and Gregoriadis, 1974; 
Christensen et al., 2007; Pagano, 1978). However, little is known about how liposomes 
interact with the host immune system. Also, the mechanism underlying the apparently 
different outcome of such interaction remains elusive. Therefore, it is of utmost 
importance to study how the host immune system recognizes liposomes and subsequent 
immune responses after the initial recognition. Furthermore, the better understanding of 
how different liposomes interact with host immune system will also help to optimize the 
clinical use of liposomes: in the context of vaccine against infectious diseases, the 
liposomes that are more potent of activating the immune system may be more preferable, 
whereas the ones that are week immune activators may be more suitable for anti-cancer 
drug delivery purpose. 
 
NOD-LIKE RECEPTORS 
Nod like receptors (NLRs) are a group of newly identified innate immune 
receptors or pathogen recognition receptors (PRRs)(Gross et al., 2011; Ogura et al., 2006; 
Schroder and Tschopp, 2010). The NLR family members are characterized based upon 
their signature domains with each member protein, such as the leucine-rich repeats 
(LRRs), the nucleotide-binding and oligomerization (NACHT) domain, the caspase 
recruitment domain (CARD) or pyrin (PYD) domain(Gross et al., 2011; Schroder and 
Tschopp, 2010). The NACHT domain is the only universal domain for all members of 
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NLRs and it mediates the activation of NLRs in response to their stimuli. Based upon 
phylogenetic analysis, NLRs can be further divided into 3 subfamilies; NLRPs (NLRP1-
14), NODs (NOD1-2, NOD3/NLRC3, NOD4/NLRC5, NOD5/NLRX1, CIITA), and 
IPAFs (IPAF/NLRC4 and NAIP)(Gross et al., 2011; Ogura et al., 2006; Schroder and 
Tschopp, 2010).   
So far, there are 22 NLRs members identified in human and even more in mouse 
due to genetic expansion. Like other PRRs, such as Toll-like receptors, the NLRs 
function to sense the presence of pathogens, foreign intruders, and even “self-danger” 
signals(Gross et al., 2011; Ogura et al., 2006; Schroder and Tschopp, 2010). For instance, 
Nlrp1 recognizes anthrax lethal toxin whereas Nlrc4 detects bacterial flagellin and 
components of bacterial type III and IV secretion systems(Gross et al., 2011; Ogura et al., 
2006; Schroder and Tschopp, 2010). NOD1 and NOD2 recognize bacterial cell wall 
breakdowns (mesodiaminopimelic acid and muramyl dipeptide, respectively)(Gross et 
al., 2011; Ogura et al., 2006; Schroder and Tschopp, 2010). NLRP3 appears to recognize 
the cytosolic changes within innate immune cells (e.g. macrophages) because it can sense 
a large diverse pool of activators that are structurally and functionally unrelated to each 
other(Bulua et al., 2011; Gross et al., 2011; Kepp et al., 2011; Naik and Dixit, 2011; 
Ogura et al., 2006; Schroder and Tschopp, 2010; Tschopp, 2011; West et al., 2011). 
Although much progress has been made during the last decade, in contrast to TLRs--the 
function of which have been extensively studies during the last two decades, little is 
known regarding the specificity and function of most NLRs.  
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Upon activation, some of the NLRs forms a large cytosolic protein aggregates, 
termed “inflammasomes”(Gross et al., 2011; Ogura et al., 2006; Schroder and Tschopp, 
2010). It functions to induce caspase-1 autocleavage and activation, which mediates the 
proteolytic processing of immature IL-1β into its mature and bioactive form. 
Additionally, active caspase-1 has also been shown to direct pyroptosis, a specialized cell 
death that is different from apoptosis or necrosis(Kepp et al., 2010; Miao et al., 2011; 
Schroder and Tschopp, 2010; Strowig et al., 2012). Although some NLRs can form 
inflammasomes when they are activated by their cognate ligands/stimuli, the composition 
of inflammasomes is not identical. For instance, NLRP3 inflammasome formation 
requires NLRP3, ASC and Caspase-1, whereas some other NLRs, such as NLRP1, do not 
involve ASC for assembly(Gross et al., 2011; Ogura et al., 2006; Schroder and Tschopp, 
2010). 
 
THE NLRP3 INFLAMMASOME 
The NLRP3 inflammasome in health and disease 
The NLRP3 inflammasome forms by NLRP3, ASC and Caspase-1. Its activation 
is unique among all PRRs because a large pool of diverse stimuli are known to induce the 
formation of NLRP3 inflammasome(Gross et al., 2011; Jin and Flavell, 2010; Kepp et al., 
2011; Ogura et al., 2006; Schroder and Tschopp, 2010; Tschopp, 2011). Notably, these 
activators are structurally and functionally unrelated, which makes the activation 
mechanism of NLRP3 inflammasome more mysterious. 
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So far, a number of studies have identified more than 30 activators of the NLRP3 
inflammasome, and the list is still growing (see Table 1.1)(Gross et al., 2011; Jin and 
Flavell, 2010; Kepp et al., 2011; Tschopp, 2011). The activators of NLRP3 
inflammasome range from pathogenic bacteria and viruses (e.g. listeria, adenovirus), to 
environmental insults (e.g. silica crystals) and self-danger signals (e.g. ATP, uric acid 
crystals). Although these activators differ significantly in their structure, function, and 
clinical relevance, it appears that they can transmit common signal(s), via a not yet 
completely understood mechanism, that ultimately drives the assembly of the NLRP3 
inflammasome and leads to the maturation and release of powerful proinflammatory 
cytokines, such as IL-1β and IL-18(Kepp et al., 2011; Schroder and Tschopp, 2010; Zhou 
et al., 2011). 
  
9 
Table 1.1. List of activators of NLRP3 inflammasome 
 
Activator class Activators 
Environmental insults Ultraviolet light 
Asbestos crystals 
Silica crystals 
Skin irritants 
Endogenous danger signals ATP 
Uric acid crystals 
Glucose 
Amyloid β 
Hyaluronan 
Immune adjuvant Alum 
Complete Freunds adjuvant 
Pathogen and its associated molecules Listeria monocytogenes 
Influenza virus 
Adenovirus 
Sendai virus 
Candida albicans 
Saccharomyces cerevisiae 
Hemozoin 
Bacterial pore-forming toxin 
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Synthetic materials 
 
 
Titanium particles 
Polymeric nanoparticles 
PLGA particles 
Gold nanoshell particles 
 
 
 
Mutations in the NLRP3 inflammasome machinery, namely the Nlrp3 gene, are 
frequently associated with many human diseases(Kingsbury et al., 2011; Strowig et al., 
2012; Vandanmagsar et al., 2011; Zaki et al., 2011). This is due to the fact that the 
dysregulated activation of the NLRP3 inflammasome triggers the release of 
proinflammatory cytokine, and the elevation of systemic and local concentrations of these 
cytokines are known to mediate undesirable inflammation associated with many 
devastating autoinflammatory diseases (see Table 1.2).  
Besides genetic variance, self metabolic products or environmental insults are 
also capable of activating the NLRP3 inflammasome(Strowig et al., 2012). For instance, 
the accumulation of uric acid—a metabolic product—at joints can induce chronic local 
inflammation and pain, the symptom of which is usually referred as “gouty arthritis” or 
“gout”(Kingsbury et al., 2011; Martinon et al., 2006; Punzi et al., 2012; Rock et al., 2012; 
Smith et al., 2011). Similar to uric acid, silica crystal is one of the major causal agents for 
occupational health problems, such as silicosis. The inhalation of silica particles activates 
the NLRP3 inflammasome in the airway and lung, sensitizes the epithelial cells and 
induces chronic inflammation in the upper respiratory tract. If left untreated, many 
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workers exposed to silica particles may eventually develop pulmonary fibrosis(Cassel et 
al., 2008; Dostert et al., 2008; Hornung et al., 2008).  
Accumulating evidence has indicated that many other metabolic products, which 
are of non-crystalline nature, also activate the NLRP3 inflammasome to initiate 
inflammatory responses that significantly contribute to the manifest of clinical 
problems(Strowig et al., 2012). For instance, the activation of NLRP3 inflammasome by 
human islet polypeptide has been shown to play a major role in facilitating the 
development of type II diabetes(Masters et al., 2010). Moreover, the NLRP3 
inflammasome has been identified as the missing link that connects high fat containing 
diet with obesity and insulin resistance. Saturated fatty acid, which is highly enriched in 
high-fat diet, is the trigger for NLRP3 inflammasome activation. Consequently, released 
IL-1β will bind to IL-1R that can interfere with insulin signaling(Wen et al., 2011). 
In conclusion, solid evidence has suggested a critical role of NLRP3 
inflammasome in a number of autoinflammatory or metabolic diseases. Thus, it is of 
utmost importance to further investigate the activation mechanism of NLRP3 in the 
context of various human diseases. 
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Table 1.2. List of human diseases associated with dysregulated NLRP3 
inflammasome activation 
 
Diseases associated with dysregulated 
NLRP3 inflammasome activation 
Activators 
Gout Uric acid crystals 
Asbestosis Asbestos crystals 
Silicosis Silica crystals 
Atherosclerosis  Cholesterol crystals 
Alzheimer’s disease Amyloid β 
Parkinson’s disease α-synuclein 
Type II diabetes Fatty acid and/or self-danger signals 
Cancer Self-danger signals (e.g. ATP, uric acid) 
Obesity Fatty acid and/or self-danger signals 
Pathogen-infection Viruses, bacteria, and/or pathogen 
associated molecules 
Geographic atrophy Alu RNA 
Allergy Environmental insults (e.g. allergic 
substances) 
 
 
 
Activation mechanisms of the NLRP3 inflammasome 
Although many activators of NLRP3 have been identified in the last decades, the 
precise molecular mechanism that leads to the activation of the NLRP3 inflammasome 
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remains elusive. This is at least in part due to the lack of a universal pathway that is 
responsible for NLRP3 inflammasome activation by all its stimuli. However, at least 
three models have been proposed for activating the NLRP3 inflammasome(Kepp et al., 
2011; Schroder and Tschopp, 2010; Tschopp and Schroder, 2010) (see Figure 1.1.). 
 
 
 
Figure 1.1: Mechanisms of NLRP3 inflammasome activation. Three models have 
been proposed for NLRP3 inflammasome activation: the first model involves potassium 
efflux. Activators of NLRP3 inflammasome, such as ATP and crystals, can induce 
potassium depletion in the cytoplasm, a required step for NLRP3 inflammasome 
activation; the second model involves rupture of lysosome and subsequent release of 
lysosomal contents, such as cathepsins. This will somehow lead to the assembly of 
NLRP3 inflammasome via an unidentified mechanism; the last model involves oxidative 
stress, in which the mitochondria is damaged upon stimulation of NLRP3 inflammasome 
activators. This will lead to the accumulation of mitochondrial reactive oxygen species 
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(ROS), that can somehow transmit signals that directs the assembly of NLRP3 
inflammasome. Although a large body of evidence has supported these models 
respectively, it appears that a unifying model that can incorporate all three mechanisms 
has yet to be further identified and explored. 
 
 
 
The first model involves potassium. In 2007, Tschopp and colleagues first 
demonstrated that the blockade of potassium efflux could inhibit NLRP3 inflammasome 
activation(Petrilli et al., 2007). Later studies have also confirmed that potassium efflux is 
required NLRP3 inflammasome activation by most, if not all activators(Cassel et al., 
2008; Eisenbarth et al., 2008; Gross et al., 2011). Although these data unify a critical role 
of reducing cytosolic potassium level in driving the assembly of the NLRP3 
inflammasome, the mechanism involved remains largely unknown.  
The second model for NLRP3 inflammasome activation involves lysosome 
rupture and subsequent release of lysosomal contents, which somehow induce the 
activation of the NLRP3 inflammasome. This model seems to apply to most particulate 
activators because it is conceivable that these large particles may induce phagocytic stress 
in macrophages, leading to the breakage of lysosome membrane and passive release of 
lysosomal contents to the cytosol. Latz and colleagues are the first group to identify the 
lysosomal cathepsin B, a cysteine protease, as a critical player for crystals-induced 
inflammasome activation(Duewell et al., 2010; Halle et al., 2008; Hornung et al., 2008). 
They proposed a “lysosome-cathepsin B” model in which the phagocytosed crystals are 
believed to trigger cathepsin B release from phagolysosome and induce NLRP3 
inflammasome assembly and activation. However, their results were solely based on a 
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cathepsin B inhibitor, CA-074-Me.  Consequently, this model was recently challenged 
based upon the fact the genetic ablation of cathepsin B had little effect on NLRP3 
inflammasome activation(Dostert et al., 2009). It appears that the off-target side effect of 
CA-074-Me is likely to interfere with the data interpretation. In addition to cathepsin B, 
Latz and colleagues have recently proposed a role for other lysosomal cathepsins, such as 
cathepsin L, in driving the NLRP3 inflammasome activation(Duewell et al., 2010). 
However, it remains to be further investigated whether multiple cathepsins play a 
redundant role in directing NLRP3 inflammasome activation. 
The third model involves reactive oxygen species (ROS), which was first brought 
up by Tschopp and his colleagues in 2008(Dostert et al., 2008). They initially proposed 
that ROS generated by NADPH oxidase (NOX) during phagocytosis of particles. As 
ROS are important signaling molecules that can directly or indirectly modify other 
cellular components or molecules, Tschopp reasoned that ROS might also play a role in 
NLRP3 inflammasome activation. In fact, the blockade of ROS by anti-oxidant prevented 
NLRP3 inflammasome activation. However, the “ROS” model was also challenged by 
others because knocking down of each individual NOXs or their common subunit did not 
significantly affect NLRP3 inflammasome activation(Bauernfeind et al., 2011; Hornung 
et al., 2008). In 2011, Tschopp’s group further investigated the source of ROS during 
NLRP3 inflammasome activation, and they found that ROS are mainly from 
mitochondria, but not NOXs(Zhou et al., 2011). They elegantly showed solid evidence 
suggesting that mitochondrial ROS plays a key role in directing the NLRP3 
inflammasome activation. Subsequent studies have also found that other contents 
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released from mitochondria also play a role in NLRP3 inflammasome activation(Misawa 
et al., 2013; Nakahira et al., 2011). For instance, unoxidized mitochondrial DNA 
(mtDNA) are shown to activate AIM2 inflammasome which further enhanced the 
generation of more mature IL-1β(Nakahira et al., 2011). Additionally, the oxidized 
mtDNA is able to bind to NLRP3 to directly induce the assembly of NLRP3 
inflammasome(Shimada et al., 2012). These findings clearly suggest that mitochondria 
play a critical role in directing the NLRP3 inflammasome activation. Although 
mitochondrial ROS is known to signal the assembly of NLRP3 inflammasome, the 
mechanism involved remains largely unknown. 
 
OXIDATIVE STRESS AND NLRP3 INFLAMMASOME 
Mitochondria regulate NLRP3 inflammasome activation 
Mitochondrion is an ancient cellular organelle that provides energy for essentially 
all biological processes within the cell. Notably, studies during the last several decades 
have clearly suggested additional roles of mitochondria in regulating other 
pathophysiological events(Tschopp, 2011). For example, a number of neurodegenerative 
diseases, namely Alzheimer’s diseases and Parkinson’s diseases, have been closely linked 
to malfunctioned mitochondria. Additionally, mitochondrial contents and related 
signaling pathways are key players in shaping the proper immune responses to bacterial 
and virus infections. MAVS (mitochondrial anti-viral signaling protein) has been one of 
the best examples for this. Solid evidence has indicated that MAVS plays a key role in 
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RIG-I like receptor signaling pathway and it regulates antiviral innate immune responses 
via directing type I interferon production(Hou et al., 2011; Seth et al., 2005). 
Recently, Tschopp and colleagues have revealed a novel role of mitochondria in 
regulating the NLRP3 inflammasome activation(Zhou et al., 2011). They found that 
blocking of mitochondrial respiratory chain, which results in ROS elevation, could 
induce spontaneous NLRP3 inflammasome activation in the complete absence of NLRP3 
exogenous agonists. Moreover, the mtDNA released from mitochondria upon NLRP3 
agonists stimulation also contributes to the proinflammatory responses(Nakahira et al., 
2011). Similarly, it has been shown that genetic knocking-down of a mitochondrial inner 
membrane channel, VDAC (voltage dependent anion channel), attenuates NLRP3 
inflammasome activation(Zhou et al., 2011). Later studies have also indicated that the 
mitochondrial membrane potential is significantly altered upon stimulation with NLRP3 
agonists(Barlan et al., 2011; Zhong et al., 2013). This alternation in membrane potential 
seems to perfectly correlate with the dynamics of NLRP3 inflammasome activation. 
Nonetheless, it appears that mitochondria can regulate the activation of NLRP3 
inflammasome at multiple levels, and the combination of such events ensures the 
complete activation of the NLRP3 inflammasome. In summary, mitochondria sense the 
cellular abnormality and transmit signals to induce downstream assembly of the NLRP3 
inflammasome and proinflammatory cytokine processing and secretion. 
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Calcium and NLRP3 inflammasome 
Although potassium has been widely accepted as the key player during NLRP3 
inflammasome activation(Gross et al., 2011; Schroder and Tschopp, 2010), how cytosolic 
potassium depletion facilitates the assembly of NLRP3 inflammasome remains largely 
unknown. In addition to potassium, a role of calcium mobilization has been proposed in 
NLRP3 inflammasome activation. Horng and her colleagues have shown that blocking 
calcium flux was able to inhibit NLRP3 inflammasome activation by many NLRP3 
agonists, and they further revealed a role of CHOP transcription factor in directing ATP-
induced NLRP3 inflammasome activation(Murakami et al., 2012).  
Two recent studies have also indicated that extracellular calcium elevation can be 
recognized by the macrophages as a “self-danger” signal that activates the calcium 
sensing receptors (CaSR) that can induce an IP3R-mediated calcium mobilization from 
ER(Lee et al., 2012; Rossol et al., 2012). This event can, via unknown mechanism, 
regulate NLRP3 inflammasome activation by many activators.  
Despite the evidence indicating a role of calcium in regulating NLRP3 
inflammasome activation, little is known regarding how the calcium mobilization is 
triggered and how the calcium would fit into other known models for NLRP3 
inflammasome activation. Particularly, because both mitochondrial ROS and calcium are 
important for NLRP3 inflammasome activation, how these key players are connected is 
unclear. Moreover, the identity of potential calcium channel and how elevated calcium 
induces NLRP3 inflammasome assembly remain to be further investigated.  
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TRPM2 (TRANSIENT RECEPTOR POTENTIAL MELASTATIN 2) CHANNEL  
An overview of the TRPM2 channel 
Transient receptor potential (TRP) proteins are comprised of a large family of 
cation-permeable ion channels that are homologues of the Drosophila TRP protein(Link 
et al., 2010; Sumoza-Toledo and Penner, 2011; Yamamoto et al., 2008). The mammalian 
TRP superfamily has 28 members, and can be grouped into six subfamilies: canonical or 
classic (C), polycystin (P), vanilloid (V), melastatin(M), mucolipin (ML) and ankyrin (A). 
The TRP protein is typically characterized by six-transmembrane domains, with both N- 
and C-termini oriented toward the cytosolic space. The cation fluxes occur between the 
fifth and sixth transmembrane domains. The TRP-melastatin subfamily (TRPM), named 
for melastatin (a tumor suppressor), contains 8 family members: TRPM1–TRPM8. Most 
TRPM channels (TRPM1–6, and TRPM8) have multiple variants, either as a full-length 
protein or a short splicing variant, which might explain the complex biological roles of 
TRPMs, such as modulating the function, ion selectivity and cellular localization of these 
cation channels. Nonetheless, further study is still needed to delineate the precise function 
of each channel variants in different cells.  
TRPM2 is non-selective multifunctional cation channel, which is Ca2+ 
permeable(Takahashi et al., 2011; Yamamoto et al., 2010). It contains the N-terminus 
homology domain (MHR), the transmembrane domain (TM) coil-coil domain and C-
terminus activation domain (Nudix-like domain, NUDT9-H). The human TRPM2 gene is 
located in chromosome 21q22.3, and consists of 32 exons. The human TRPM2 gene 
encodes a protein of 1503 amino acids. Slightly different from its human homologue, the 
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mouse TRPM2 gene contains 34 exons. The TRPM2 protein comprises six 
transmembrane segments, flanked by the intracellular N- and C-termini, with the pore-
forming channel domain located between the fifth and sixth transmembrane domains.  
Although several studies have revealed multiple activators for TRPM2 
channel(Takahashi et al., 2011; Yamamoto et al., 2010), such as ADP-ribose 
(ADPR)(Sumoza-Toledo and Penner, 2011), cyclic ADP-ribose (cADPR), calcium, and 
H2O2, ADPR has been generally accepted as the primary activating/gating agent of 
TRPM2 channel. ADPR binds to the NUDT9-H domain on the C-terminus of TRPM2 
and is subsequently hydrolyzed to ribose 5-phosphate and AMP, which is most likely due 
to the enzymatic activity of the C-terminus of TRPM2. Notably, this enzymatic feature of 
TRPM2 has been proposed to provide a negative regulation mechanism for controlling 
the opening of TRPM2 because AMP is known to antagonize ADPR-mediated gating of 
TRPM2(Sumoza-Toledo and Penner, 2011). Upon binding of TRPM2 gating agents (e.g. 
ADPR), TRPM2 channels will transiently open and allow the pass through of a number 
of cations, such as Na+, K+ and Ca2+, into the cell. A linear current–voltage relationship, 
characterizes TRPM2 currents and TRPM2 has a remarkably long open-time (several 
seconds) in comparison with other cationic channels(Rossol et al., 2012; Sumoza-Toledo 
and Penner, 2011; Takahashi et al., 2011). 
TRPM2 is expressed in many tissues and organs with its highest level seen in 
brains(Sumoza-Toledo and Penner, 2011). Due to the unique expression pattern, the role 
of TRPM2 has been extensively studied in neurons and more importantly, in the context 
of a number of neurodegenerative diseases, such as Alzheimer’s diseases, multiple 
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sclerosis, and Parkinson’s disease. Mice deficient in TRPM2 showed significant 
protection in animal models of several neurological diseases, suggesting that TRPM2-
mediated calcium mobilization positively regulates the onsite/progression of such 
diseases(Naziroglu, 2011).  
Besides its expression in brains, TRPM2 has also been detected in other tissues 
such as spleen, bone marrow, heart, liver and lung, and in a number of different cell types 
like pancreatic β-cells, endothelial cells, epithelial cells, cardiomyocytes and a panel of 
immune cells (e.g. neutrophils, monocytes/macrophages and T cells)(Sumoza-Toledo and 
Penner, 2011; Takahashi et al., 2011). However, in contrast to its role in brain neurons 
and microglia, the role of TRPM2 in other cells has not yet been largely explored. It is 
conceivable that the TRPM2-mediated cation fluxes may presumably play regulatory 
roles in shaping the function of many different cells in which TRPM2 is expressed. 
 
TRPM2 channel and oxidative stress 
Due to the fact that TRPM2 channel can open under oxidative stress conditions, 
much attention has been paid to the role of TRPM2 in sensing the redox change within 
the cell(Sumoza-Toledo and Penner, 2011; Takahashi et al., 2011). The generation of 
reactive oxygen species (ROS) is a signature event when cells are under oxidative stress 
triggered by foreign insults or self-genetic instability. ROS are reactive molecules that are 
able to modulate almost all other molecules within the cell, such as lipid, protein, DNA, 
and RNA(Bulua et al., 2011; Kepp et al., 2011; Naik and Dixit, 2011; Tschopp, 2011). 
Therefore, it has been widely accepted that ROS function as a signaling messenger or 
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intermediate to direct downstream events which ultimately regulate/alter the activity of 
certain molecule or the function of a cellular organelle.  
Recent studies have linked TRPM2 activity with oxidative stress by showing that 
gating of TRPM2 channel is frequently associated with oxidative damage in the 
cell(Takahashi et al., 2011). This notion is supported by the fact that oxidative stress-
induced DNA damage in the nucleus is known to induce the accumulation and release of 
abundant free ADPR, which can bind to TRPM2 to induce cationic fluxes(Naziroglu, 
2007; Perraud et al., 2003). Additionally, it has also been proposed that the ADPR 
released from mitochondria, another source of cellular ADPR, might also contribute to 
the TRPM2 opening under oxidative stress, because mitochondria are highly sensitive to 
environmental stress which likely to converts such stress signals to oxidative damage in 
the cell(Perraud et al., 2005).  
From an immunological prospect, TRPM2 is also a critical player in the immune 
system. For instance, seminal studies by Mori group have clearly demonstrated the key 
role of TRPM2 in mediating oxidative stress (e.g. ROS) induced upregulation of 
chemokine expression, which contributes to the aggregation of local proinflammatory 
responses(Yamamoto et al., 2008). This is of particular interest in innate immunity 
against microbes because several studies have revealed that mice deficient in TRPM2 are 
defective in controlling the pathogenesis of bacterial infection. For instance, TRPM2 
deficiency has been shown to drastically affect the ability of mouse immune system to 
restrict Listeria monocytogenes infection(Knowles et al., 2011). Interestingly enough, as 
Listeria monocytogenes are known activator of NLRP3 and AIM2 inflammasomes(Kim 
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et al., 2010), we reasoned it would be interesting to investigate the role of TRPM2-
mediated calcium mobilization in inflammasome activation, especially considering the 
fact that calcium is a critical player for regulating inflammasome activity. 
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CHAPTER 2 
RATIONALE AND DISSERTATION OUTLINE 
Liposomes are particles consisting of self-aggregated lipids and are commonly 
used as effective immune adjuvants and efficient drug delivery vehicles to treat various 
infectious and cancerous diseases(Al-Jamal and Kostarelos, 2011; Allison and 
Gregoriadis, 1974; Christensen et al., 2007; Slingerland et al., 2012). Although previous 
studies have indicated that liposomes can enhance the expression of chemokines, such as 
CCL2 and co-stimulatory molecules such as CD80/86 in antigen-presenting cells(Cremel 
et al., 2006; Cui et al., 2005; Vangasseri et al., 2006; Yan et al., 2007), little is known 
about whether an innate immune receptor exists to sense the presence of liposomes. 
During the past decade, a number of studies have demonstrated that particulate 
substances such as alum, silica, monosodium urate, and calcium pyrophosphate dihydrate 
crystals can induce NLRP3 (Nod-like receptor family, pyrin domain containing 3) 
inflammasome activation which mediates the secretion of biologically active IL-1β from 
macrophages(Dostert et al., 2008; Eisenbarth et al., 2008; Hornung et al., 2008; Li et al., 
2008; Martinon et al., 2006). Because liposomes are also of particulate in nature, I 
hypothesized that the NLRP3 inflammasome may serve as an innate immune sensor for 
liposomes. 
Although the precise mechanism by which the NLRP3 inflammasome is activated 
remains unknown, several stress-related cellular processes, including cytosolic depletion  
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of potassium, lysosome disruption, mitochondrial damage and intracellular calcium 
elevation have been proposed to be involved in activation of this inflammasome(Jin and 
Flavell, 2010; Murakami et al., 2012). Mitochondria are an ancient and evolutionarily 
conserved cellular organelle that play a key role in regulating the signaling pathways of 
pattern recognition receptors (PRRs)(West et al., 2011), including the NLRP3 
inflammasome. Upon stimulation with particulate stimuli, mitochondria can transmit 
stress signals to alarm the immune system via secondary signaling messengers, such as 
mitochondrial reactive oxygen species (ROS) (Kepp et al., 2011; Tschopp, 2011; West et 
al., 2011). Blocking ROS generation by mitochondria has been shown to abolish NLRP3 
inflammasome activation whereas artificial induction of mitochondrial ROS can 
spontaneously induce NLRP3-mediated IL-1β secretion(Nakahira et al., 2011; Zhou et 
al., 2011). Although it is clear that mitochondrial ROS play a pivotal role, the precise 
mechanism underlying ROS-induced NLRP3 inflammasome activation remains poorly 
understood. 
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Figure 2.1: Dissertation outline/working model. I hypothesize the charged liposomes, 
but not neutral ones, activate the NLRP3 inflammsome to induce bioactive IL-1β 
secretion from macrophages. Briefly, upon macrophage uptake of charged liposomes, it 
can induce oxidative stress which makes mitochondria under stressed conditions. This 
will further lead to the accumulation of mitochondrial reactive oxygen species and 
subsequently induce a calcium influx via the plasma membrane TRPM2 channel. The 
gating of TRPM2 channel can be achieved by at least two ways, which depends on free 
ADP-ribose release from nucleus or direct H2O2 opening of the TRPM2 channel, 
respectively. The elevation in intracellular calcium concentration will then create a 
preferable ionic environment which favors the assembly of the NLRP3 inflammasome 
and subsequent caspase-1 activation, proteolytic processing of pro-IL-1β, and release of 
bioactive mature IL-1β. This process will also be accompanied by cytosolic depletion of 
potassium (potassium efflux). However, the precise relationship between potassium and 
calcium mobilizations in NLRP3 inflammasome activation process needs further 
investigation. 
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CHAPTER 3 
MATERIALS AND METHODS 
Reagents 
1,2-Dioleoyl-3-trimethylammonium-propane (DOTAP), 3β-[N-(N',N'-
dimethylaminoethane)-carbamoyl]cholesterol hydrochloride (DC-Chol), 
dimethyldioctadecylammonium (bromide salt) (DDA), 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-
dimyristoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DMPG) and L-α-
phosphatidylcholine (soy extract) were purchased from Avanti Polar Lipids (Alabaster, 
AL). Track-etch polycarbonate membranes (2 µm, 800 nm, 400 nm, 200 nm and 100 nm) 
were from Millipore, The Lipex liposomes extruder was from Northern Lipids and other 
common lab chemicals and reagents were from Sigma-Aldrich and Fisher Scientific. 
Cholesterol, ovalbumin, silica, ATP, phorbol 12-myristate 13-acetate (PMA), 
cytochalasin D, uricase, bafilomycin A1, Ca-074-Me, H2O2, rotenone, antimycin and 
BAPTA-AM were from Sigma-Aldrich. Ultrapure LPS, zymosan, and poly(dA:dT), and 
glibenclamide were from Invivogen. zYVAD-fmk, APDC and DPQ were from Alexis 
Biochemicals. DPI was from Calbiochem. Monosodium urate crystals, VAS2870 and 
NAC were from Enzo Lifescience. Imject Alum and streptavidin-HRP were from Pierce. 
Lipofectamine 2000, MitoSOX and fura-2-AM were from Invitrogen. Calcium free and 
calcium containing DMEM media were from US Biologicals. The lactate dehydrogenase 
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(LDH) assay kit was from Roche. Antibodies used for immunoblotting were as follows: 
anti-mouse caspase-1 (sc-514, Santa Cruz Biotechnology), anti-mouse β-actin (sc-1615 
HRP, Santa Cruz Biotechnology) and anti-mouse IL-1β (AF-401-NA, R&D systems). 
Antibodies used for determining OVA-specific IgG isotypes IgG1 and IgG2b were from 
Biolegend, and the antibody for mouse IgG2c was from Bethyl Laboratories. 
 
Liposomes formulations 
A total of 16 different liposomes formulations (see Table 3.1) were produced by 
Encapsula NanoSciences. The liposomes were made using the dehydration-rehydration 
method. The lipids were dissolved in chloroform in a round bottom flask, and the solvent 
in the flask was then evaporated using a Büchi (RE-121) rotary evaporator (Flawil, 
Switzerland) under a vacuum for 4 hours, resulting in the formation of a thin lipid film. 
The thin lipid film was hydrated with deionized water for 2 hours at 37°C and then over 
night at 4°C. The milky solution of liposomes was extruded 25 times through an 
appropriately sized polycarbonate membrane filter using a Lipex extruder connected to a 
high-pressure nitrogen cylinder to produce liposomes of the desired sizes. For example, 
liposomes were passed through a 100-nm polycarbonate membrane filter 25 times to 
produce 100-nm liposomes.  
To formulate ovalbumin-encapsulated liposomes, the thin lipid film was hydrated 
with a solution of ovalbumin in deionized water. The liposomes were sized to 400 nm. 
The non-encapsulated ovalbumin was separated using 100K dialysis membrane tubing 
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(Spectrum Laboratories). The amount of the encapsulated ovalbumin was determined by 
BCA assay using a BCA protein assay kit (ThermoFisher Scientific). 
 
Table 3.1 Liposome formulations  
 
Lipid 
composition 
Lipid Molar percentage Size (nm) Concentration (mg/ml) 
DOTAP 100  100 10  
DOTAP 100 200 10  
DOTAP 100 400 10 
DOTAP 100 800 10 
DOPC 100 100 10 
DOPC 100 200 10 
DOPC 100 400 10 
DOPC 100 800 10 
DOTAP:DOPC 50:50 100 20 
DOTAP:DOPC 80:20 100 10 
DOTAP:DOPC 90:10 100 10 
DPPC:DMPG 70:30 100 10 
DC-Cholesterol  100 100 10 
DDA 100 100 10 
L-α-PC: 
Cholesterol 
70:30 2000 23 
DOTAP-OVA  
(OVA 
encapsulated) 
100 400 10 mg/ml of lipid and 2 
mg/ml of encapsulated 
ovalbumin 
 
 
 
Cell culture and stimulation  
Human THP-1 cells (ATCC) were grown in RPMI-1640 medium supplemented 
with 10% (vol/vol) FBS. THP-1 cells were primed with PMA (100 nM) for 3h, washed 
three times and cultured overnight in serum-free DMEM medium. The cells were then 
stimulated with either liposomes or crystals for 18h, and the supernatants were collected 
for the detection of human IL-1β by ELISA. Bone marrow-derived macrophages 
(BMDMs) were generated by culturing the mouse bone marrow cells in the presence of 
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20% vol/vol L929 conditional media as previously described(Hornung et al., 2008; Wen 
et al., 2011). After pretreatment with ultrapure LPS (100 ng/ml for primary BMDMs and 
50 ng/ml for immortalized macrophages) for 16-18h, the BMDMs were stimulated with 
ATP for 30min unless otherwise indicated or liposomes, alum, silica, MSU crystals or 
H2O2 for 6h. Poly(dA:dT) was transfected into the macrophages using Lipofectamine 
2000 (4 µg/ml) according to manufacturer’s instructions. For the experiments using 
chemical inhibitors, the inhibitors were added 45 min prior to stimulation with the 
NLRP3 inflammasome agonists. The blockade of potassium efflux with a high 
concentration of KCl was performed as previously described(Eisenbarth et al., 2008). For 
the experiments using calcium-free medium, BMDMs were first primed with LPS for 18h 
in calcium-containing DMEM, washed four times with PBS and then cultured in calcium-
free DMEM in the presence of inflammasome agonists. Supernatants and cell lysates 
were collected for ELISA and immunoblotting analyses. Immortalized murine 
macrophages from Nlrp3−/−, Asc−/−, Capase 1−/−, Nlrc4−/−, Cathepsin B−/−, Aim2−/− mice 
and their corresponding wild-type control cells were generously provided by Dr. 
Katherine Fitzgerald and as previously described(Hornung et al., 2008).  
 
Enzyme-linked immunosorbent assay  
Paired (capture and detection) antibodies and standard recombinant proteins for 
mouse IL-1β, tumor necrosis factor and IL-6 (from eBioscience) were used to quantify 
the cytokine levels in cell culture supernatants according to the manufacturer's 
instructions. Briefly, 96-well plates were coated with capture antibodies overnight for 
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each cytokine tested. On the next day, the plates were washed and blocked with 5% non-
fat milk dissolved in PBS-T buffer for 2 hours. After washing the plates, dilutions of cell 
culture supernatants were added into each well and incubated for 2 hours. Detection 
antibodies (biotin-labeled) were added after washing out the diluted samples, and the 
plates were incubated for another 2 hours. Then the plates were washed and streptavidin-
labeled HRP was added for incubation of 1 hour. The plates were washed and the HRP 
substrate (TMB) was added and the reaction can be stopped by 1M H2SO4. The values of 
OD450 were subsequently measured.  
 
Mitochondrial ROS detection 
Mitochondrial ROS levels were measured using MitoSOX (Invitrogen). Briefly, LPS-
primed cells were treated with liposomes for 6 h, loaded with 4 µM of MitoSOX for 15 
min and washed twice with sterile PBS. The mean fluorescence intensity was determined 
using a FACSCantoflow cytometer (BD Bioscience), and the data were analyzed using 
FlowJo software (Treestar). 
 
Fluorometric measurement of [Ca2+]i 
The [Ca2+]i was measured in single cells as previously described(Han et al., 
2006). Briefly, cells were loaded for 30 min at 37°C with 2µM fura-2 AM in Tyrode 
solution containing 138 mM NaCl, 2.7 mM KCl, 1.06 mM MgCl2, 1.8 mM CaCl2, 5.6 
mM glucose and 12.4 mM HEPES (pH 7.4, adjusted with NaOH). The fluorescence 
emission at 510 nm of fura-2 excited at 340 nm and 380 nm was acquired and analyzed 
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offline with the NIS-Elements Advanced Research software package (Nikon) using an 
inverted Nikon Ti-E microscope equipped with a Xenon lamp (Hammamatsu), a 40x 1.30 
NA objective (Nikon) and an Evolve 512 EMCCD camera (Photomatrics). The EMCCD 
camera was cooled to -80°C during imaging. 
 
Quantitative real-time PCR analysis 
RNA was isolated from murine bone marrow derived macrophages and was 
reverse transcribed. Quantitative real-time PCR analysis was performed using the 
StepOnePlus Real-time PCR system (Applied Biosystems). All gene expression data are 
presented as the expression relative to HPRT1. The primer sequences are described in 
Table 3.2. 
 
Table 3.2 Primers sequences for real-time PCR analysis. 
 
Mouse 
gene 
Forward Reverse 
Il1b CTGCAGCTGGAGAGTGTGG GGGGAACTCTGCAGACTCAA 
Nlrp3 ATGGCTGTGTGGATCTTTGC CACGTGTCATTCCACTCTGG 
Hprt1 CTGGTGAAAAGGACCTCTCG TGAAGTACTCATTATAGTCAA
GGGCA 
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In vivo mouse peritonitis model 
Peritonitis was induced by the intraperitoneal injection of stimuli. Briefly, 6- to 8-
week-old mice were intraperitoneally injected with 1 mg MSU crystals, DOTAP 
liposomes or 0.2 mg zymosan dissolved in 0.5 ml sterile PBS. Six hours after injection, 
the mice were sacrificed by exposure to CO2 and the peritoneal cavities were washed 
with 8 ml cold PBS. The recruited polymorphonuclear neutrophils present in the 
peritoneal lavage fluid were quantified by flow cytometry using the neutrophil markers 
Ly6G (BD Bioscience) and CD11b (eBioscience). The samples were acquired on a 
FACSCantoflow cytometer (BD Biosciences) and the data were analyzed using FlowJo 
software (Treestar). 
 
Immunization 
6- to 8-week-old mice deficient in TRPM2 or IL-1R and the corresponding wild-
type controls were subcutaneously immunized with ovalbumin alone (40µg/mouse), 
ovalbumin-encapsulated DOTAP liposomes or ovalbumin mixed with LPS, and the 
animals were boosted once after two weeks. Ten days after the final immunization, the 
mice were sacrificed by exposure to CO2 and the immune sera from the periphery blood 
were isolated. 
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Statistical analyses 
All data are shown as mean ± s.d. or mean± s.e.m.. Statistical analysis was performed 
using a two-tailed Student’s t-test for all studies. For all tests, P-values less than 0.05 
were considered statistically significant. 
 35 
CHAPTER 4 
RESULTS 
AIM1: DETERMINE WHETHER LIPOSOMES ACTIVATE NLRP3 
INFLAMMASOME TO INDUCE BIOACTIVE IL-1β FROM MACROPHAGES 
Charged liposomes, but not neutral ones, induce mature IL-1β release from 
macrophages 
It is generally accepted that a “two-step” process is necessary for NLRP3 
inflammasome-mediated IL-1β release. The first step requires NF-κB activation to induce 
synthesis of pro-IL-1β, whereas the second step involves assembly of a large cytosolic 
protein complex, termed inflammasomes, which lead to caspase-1 activation. Caspase-1 
then cleaves pro-IL-1β into its mature form(Gross et al., 2011). To determine whether 
liposomes can trigger activation of the NLRP3 inflammasome, we first tested whether 
several liposomes, consisting of different phospholipids, can induce bioactive IL-1β 
release in macrophages. Cationic (DOTAP, DC-Chol, and DDA) and anionic (DPPC-
DMPG) liposomes elicited IL-1β release from lipopolysaccharide (LPS)-primed murine 
bone marrow-derived macrophages (BMDMs) and PMA-primed human THP-1 cells 
(Figure 4.1), and the levels of secreted IL-1β were dependent on the dose and size of the 
liposomes (Figure 4.2). Procaspase-1 was auto-cleaved after stimulation with charged 
liposomes, and active caspase-1 was responsible for the maturation of IL-1β (Figure 4.3).  
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Unlike IL-1β release, the secretion of both TNF and IL-6, which relies on NF-κB 
activation, was not enhanced in LPS-primed BMDMs after liposomes stimulation 
(Figure 4.4a, b). Consistently, liposomes alone did not induce either TNF or IL-6 
secretion in unprimed macrophages (Figure 4.4c). In sharp contrast to the charged 
liposomes, neutral liposomes, such as DOPC and PC-Chol liposomes, failed to trigger IL-
1β secretion (Figure 4.1 and Figure 4.5a, b). However, the incorporation of cationic 
lipids into neutral liposomes rescued IL-1β secretion (Figure 4.5c), which suggests that 
the charge of liposomes determines their ability to induce IL-1β release. Furthermore, 
although liposomes induced low levels of cytotoxicity in macrophages (Figure 4.6), ATP 
and uric acid, two known NLRP3 inflammasome agonists that are released from dying 
cells(Mariathasan et al., 2006; Martinon et al., 2006), were not intermediates responsible 
for liposome-induced IL-1β secretion (Figure 4.7). 
 
 
 
Figure 4.1: Charged liposomes, but not neutral ones, induce IL-1β secretion from 
macrophages. ELISA for IL-1β from the supernatants of (a) LPS-primed wild-type 
BMDMs or (b) PMA-primed THP1 cells that were stimulated with either the indicated 
liposomes (30 µg/ml for BMDMs and 50 µg/ml for THP1 cells) or alum (250 µg/ml for 
BMDMs and 500 µg/ml for THP1 cells). Data are shown as mean ± s.d., and all data are 
representative of at least three independent experiments. 
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Figure 4.2: Charged liposomes induce IL-1β secretion in a dose and size dependent 
manner. ELISA for IL-1β from supernatants of PMA-primed THP1 cells that were 
stimulated with DOTAP liposomes of different doses (a) or sizes (b, 100 nm, 200 nm, 
400 nm or 800 nm in diameter, respectively) for 16 h. Data are shown as mean ± s.d., and 
are representative of three independent experiments.  
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Figure 4.3: Charged liposomes activate caspase-1 to induce bioactive IL-1β release. 
(a) Immunoblots of procaspase-1, activated caspase-1 (p10), pro-IL-1β and cleaved IL-1β 
(p17) in the culture supernatants (Sup) and cell lysates (Lys) from LPS-primed BMDMs 
after stimulation with indicated liposomes or alum. (b) IL-1β from supernatants of LPS-
primed BMDMs that were pretreated with caspase-1 inhibitor (z-YVAD-fmk, 10 µM) for 
45 min followed by stimulations with indicated liposomes or alum. Data are shown as 
mean ± s.d. in b, and all data are representative of three independent experiments. 
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Figure 4.4: Charged liposomes alone do not induce secretions of TNF and IL-6. 
ELISA for TNF (a) or IL-6 (b) from supernatants of LPS-primed wild-type mouse 
BMDMs that were stimulated with indicated liposomes. (c) TNF and IL-6 from 
supernatants of wild-type unprimed BMDMs treated with LPS (100 ng/ml) or indicated 
liposomes alone (30 µg/ml). Data are shown as mean ± s.d., and are representative of 
three independent experiments. 
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Figure 4.5: Neutral liposomes fail to induce IL-1β secretion in macrophages. ELISA 
for IL-1β from supernatants of LPS-primed wild-type BMDMs (a) or PMA-primed THP1 
cells (b) that were stimulated with indicated neutral liposomes for 24 h. (c) ELISA for IL-
1β from supernatants of PMA-primed THP1 cells that were stimulated with pure DOPC 
or DOTAP liposomes, or chimeric liposomes (50 µg/ml) made with various molar ratio 
of DOPC versus DOTAP. Data are shown as mean ± s.d., and are representative of at 
least three independent experiments. 
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Figure 4.6: Macrophage viabilities after treatment with charged liposomes or alum. 
The levels of released Lactate dehydrogenase (LDH) were measured from the 
supernatants of LPS-primed immortalized wild-type, Nlrp3−/− and Caspase 1−/− 
macrophages that were stimulated with the DOTAP or DPPC-DMPG liposomes (70 
µg/ml) or alum (500 µg/ml) for 6 h. Measurements were determined in triplicate and are 
shown as mean ± s.d., and data are from one of three independent experiments. 
 
 
 
The intact NLRP3 inflammasome machinery is required for liposome-induced IL-1β 
secretion 
Next, we sought to determine whether the intact NLRP3 inflammasome 
machinery was essential for liposome-induced IL-1β secretion. First, we observed that 
liposome-induced IL-1β secretion required LPS priming (Figure 4.7). Moreover, 
macrophages deficient in NLRP3, ASC or caspase-1, three key components of the 
NLRP3 inflammasome, all failed to respond to liposome stimulation after LPS priming 
(Figure 4.8). In contrast, macrophages deficient in NLRC4, another Nod-like receptor 
that recognizes bacterial flagellin(Miao et al., 2006), or AIM2 (absence in melanoma 2), 
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an immune sensor for DNA(Fernandes-Alnemri et al., 2009; Hornung et al., 2009), 
responded to charged liposomes stimulation in a manner similar to wild-type cells 
(Figure 4.8 and Figure 4.9). These data collectively suggest that charged liposomes 
induced IL-1β secretion specifically via activation of the NLRP3 inflammasome.  
To further confirm that charged liposomes activate the NLRP3 inflammasome, we 
next tested whether potassium efflux, a seemingly obligatory event during NLRP3 
inflammasome activation(Gross et al., 2011; Jin and Flavell, 2010; Ogura et al., 2006), 
was necessary for liposome-induced inflammasome activation. Indeed, the blockade of 
potassium efflux with a high concentration of KCl drastically decreased the liposome-
induced NLRP3 inflammasome activation (Figure 4.10). Similar results were also 
obtained when glibenclamide, an inhibitor that blocks potassium channels(Dostert et al., 
2009), was used (data not shown). Hereafter, we used DOTAP and DPPC-DMPG 
liposomes as the representative cationic and anionic liposomes, respectively, to 
investigate the mechanism by which charged liposomes activate the NLRP3 
inflammasome. 
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Figure 4.7: Liposomes-induced IL-1β release requires LPS priming. ELISA for IL-1β 
from the supernatants of LPS-primed or unprimed wild-type BMDMs that were 
stimulated with indicated liposomes (30 µg/ml) or alum (250 µg/ml). Data are shown as 
mean ± s.d., and are representative of three independent experiments. 
 
 
 
 
 
 
 
Figure 4.8: The NLRP3 inflammasome mediates liposomes-induced IL-1β release. 
The IL-1β levels from the supernatants of LPS-primed immortalized mouse macrophages 
from wild-type, Nlrp3−/−, Asc−/−, Caspase-1−/− or Nlrc4−/− mice that were stimulated with 
liposomes (70 µg/ml). Data are shown as mean ± s.d., and are representative of three 
independent experiments. 
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Figure 4.9: Charged liposomes activate the NLRP3, but not AIM2, inflammasome. 
(a-c) ELISA for IL-1β from supernatants of LPS-primed immortalized murine 
macrophages from wild-type, Nlrp3−/−, Asc−/−, Caspase 1−/− or Aim2−/− mice that were 
stimulated with indicated amount of empty cationic liposomes (Lipofectamine 2000) or 
poly(dA:dT)-loaded liposomes for 6 h. Data are shown as mean ± s.d., and are 
representative of three independent experiments. 
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Figure 4.10: Potassium efflux is required for liposome-induced IL-1β secretion. (a-c) 
ELISA for IL-1β from the supernatants of LPS-primed wild-type BMDMs that were 
cultured in 150 mM of KCl or NaCl followed by stimulation with liposomes or alum.  
Data are shown as mean ± s.d., and are representative of three independent experiments. 
 
 
 
IL-1R signaling is critical for the adjuvant effect of liposomes  
The mature bioactive IL-1β is a powerful proinflammatory cytokine that is 
critically involved in both innate and adaptive immunities. It functions by signaling 
through its receptor, IL-1R. Since it has been previously suggested that IL-1β-IL-1R 
signaling axis is crucial for directing Th2 responses(Shaw et al., 2011), we next tested 
whether the blockade of IL-1β-IL-1R signaling pathway would affect the humoral 
immune response induced by antigen-encapsulated liposomes. As shown in Figure 
4.11a, mice deficient in IL-1R had significantly reduced OVA-specific IgG1, the major 
subtype of antibodies, in comparison with their wild-type littermates. Notably, deficiency 
in IL-1R did not appear to affect the levels of OVA-specific IgGs when LPS was used as 
the adjuvant (Figure 4.11b). This suggests that IL-1R deficiency does not yield a 
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universal defect of mounting antibody responses. Together, these data indicate that IL-
1β-IL-1R signaling pathway is crucial for the adjuvanticity of liposomes. 
 
 
 
 
Figure 4.11: IL-1R signaling is crucial for liposomes’ adjuvant effect. (a, b) Six- to 
eight-week old female wild-type (Il1rl+/+) or Il1rl−/− mice were subcutaneously 
immunized on day 0 and day 14 with 40 µg/mouse ovalbumin (OVA) alone or the same 
amount of OVA encapsulated within DOTAP liposomes (a) or mixed with LPS (25 
µg/mouse, b). On day 24, the mice were sacrificed, and sera were collected and analyzed 
for OVA-specific IgG1, IgG2b, and IgG2c levels by ELISA. The data are shown as 
geometrical mean ± s.e.m., and are representative of at least two independent experiments 
(n=4-5 mice per group). *, p<0.05 versus controls. Statistical significance was 
determined by the standard two-tailed Student’s t-test. 
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AIM2: DELINEATE THE MOLECULAR MECHANISM BY WHICH 
LIPOSOMES ACTIVATE THE NLRP3 INFLAMMASOME  
 
Activation of the NLRP3 inflammasome requires cellular uptake of liposomes via 
the actin-dependent endocytic pathway 
NLRP3 is a cytosolic innate immune receptor which, upon activation, recruits 
ASC and procaspase-1 to assemble into the inflammasome(Ogura et al., 2006). 
Therefore, we next tested whether cellular uptake of liposomes was necessary for 
activation of the NLRP3 inflammasome. The inhibition of the endocytic pathway with 
cytochalasin D, a potent inhibitor of actin polymerization(Hornung et al., 2008), greatly 
reduced liposome-induced IL-1β secretion, whereas ATP-induced NLRP3 inflammasome 
activation, which does not require endocytic routes to activate the NLRP3 
inflammasome(Hornung et al., 2008; Mariathasan et al., 2006), was largely unaffected 
(Figure 4.12). These data suggest that the cellular internalization of liposomes is an 
essential step for liposome-induced NLRP3 inflammasome activation.  
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Figure 4.12: Activation of the NLRP3 inflammasome requires cellular uptake of 
liposomes.  IL-1β from the supernatants of PMA-primed THP1 cells that were pretreated 
with cytochalasin D before stimulation with indicated liposomes (DOTAP liposome 40 
µg/ml, DPPC-DMPG liposomes 100 µg/ml), alum (500 µg/ml) or ATP (2 mM). Data are 
shown as mean ± s.d., and are representative of three independent experiments. 
 
 
 
Lysosomal acidification and cathepsin B activity are dispensable for liposome-
induced NLRP3 inflammasome activation 
We also sought to determine whether the lysosome-cathepsin B pathway was 
involved in liposome-induced NLRP3 inflammasome activation. First, we found that the 
pharmacologic inhibition of lysosomal acidification, a process critical for crystal-induced 
inflammasome activation(Hornung et al., 2008), did not significantly affect liposome-
induced NLRP3 inflammasome-mediated IL-1β secretion (Figure 4.13a). Furthermore, 
we also observed that lysosomal cathepsin B was not necessary for liposome-triggered 
NLRP3 inflammasome activation because cathepsin B-deficient macrophages had only a 
minimal reduction in the amount of secreted IL-1β after liposome stimulation (Figure 
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4.13b). Notably, we observed that liposome-induced IL-1β secretion was decreased in 
BMDMs that were pretreated with a cathepsin B inhibitor, CA-074-Me (Figure 4.13c). 
These seemingly conflicting data may be due to the potential off-target side effects of 
CA-074-Me(Dostert et al., 2009; Hornung et al., 2008; Newman et al., 2009). Taken 
together, these data indicate that liposomes may either activate the NLRP3 
inflammasome in a lysosome-independent manner or that several lysosomal cathepsins, 
such as cathepsins B and L, are functionally redundant in mediating liposome-induced 
NLRP3 inflammasome activation. 
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Figure 4.13: Lysosomal cathepsin-B is dispensable for liposome-induced NLRP3 
inflammasome activation.  (a, c) ELISA for IL-1β from supernatants of LPS-primed 
wild-type BMDMs that were pretreated with bafilomycin A1 (50 nM and 250 nM in a) or 
CA-074-Me (10 µM in c) followed by stimulations with DOTAP or DPPC-DMPG 
liposomes (30 µg/ml) or silica (500 µg/ml). (b) ELISA for IL-1β from supernatants of 
LPS-primed immortalized murine wild-type or cathepsin B deficient (CatB−/−) 
macrophages that were stimulated with DOTAP or DPPC-DMPG liposomes (70µg/ml). 
Data are shown as mean ± s.d., and all data are representative of at least three 
independent experiments. *, p<0.05, and **, p<0.01 versus controls. Statistical 
significance was determined by the standard two-tailed Student’s t-test. 
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Charged liposomes, but not neutral ones, trigger the production of ROS production 
from mitochondria to direct NLRP3 inflammasome activation 
Although mitochondrial ROS are essential for activation of the NLRP3 
inflammasome(Kepp et al., 2011; Nakahira et al., 2011; Tschopp, 2011; Zhou et al., 
2011), a recent study also suggested a role for ROS during the first priming step of pro-
IL-1β synthesis(Bauernfeind et al., 2011). Therefore, to specifically investigate the role 
of ROS during activation of the NLRP3 inflammasome activation but not during pro-IL-
1β synthesis, we added ROS inhibitors after the synthesis of pro-IL-1β was completed. 
This was achieved through prolonged LPS stimulation to saturate NF-κB activation 
before ROS inhibition. As shown in Figure 4.14, prolonged LPS priming for 18 h 
maximized the level of NF-κB mediated transcription, which was measured by the 
production of NF-κB-dependent TNF.  
 
 
 
 
Figure 4.14: Prolonged LPS stimulation saturates LPS-induced NF-κB activation. 
ELISA for TNF from the supernatants of wild-type BMDMs that were stimulated with 
100 ng/ml LPS for various periods of time as indicated. Data are shown as mean ± s.d., 
and are representative of at least three independent experiments. 
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We then evaluated whether different liposomes could induce mitochondrial ROS 
production. Notably, only the charged liposomes, but not neutral liposomes, induced the 
robust generation of mitochondrial ROS in LPS-primed macrophages (Figure 4.15). 
Moreover, even in the absence of an LPS priming step, charged liposomes remained 
capable of increasing the mitochondrial ROS levels, suggesting that LPS pre-stimulation 
is not necessary for mitochondrial ROS induction (data not shown). Next, we used the 
pharmacological inhibitor diphenyleneiodonium (DPI), which blocks mitochondrial ROS 
production when used at high concentrations(Bulua et al., 2011; Holland and Sherratt, 
1972), to further investigate whether mitochondrial ROS were involved in liposome-
induced NLRP3 inflammsome activation. The addition of DPI prior to liposome 
stimulation drastically reduced liposome-induced mitochondrial ROS production and IL-
1β release (Figure 4.16). Notably, the reduction in IL-1β secretion was not due to the 
inhibition of NF-κB activation by DPI because neither the levels of pro-IL-1β or Nlrp3 
were significantly changed after the 18 h LPS priming step (Figure 4.17).  In contrast to 
DPI, pretreatment of the macrophage with VAS2870, which blocks NADPH oxidase 
(NOX)-generated ROS(Stielow et al., 2006), did not affect liposome-induced IL-1β 
secretion, suggesting that mitochondria, rather than NOX-derived ROS drive the NLRP3 
inflammasome activation (Figure 4.18). Moreover, because activation of the AIM2 
inflammasome by poly(dA:dT) was not affected by DPI treatment (Figure 4.16b), the 
inhibition of mitochondrial ROS seemed to specifically affect the NLRP3 inflammasome. 
Similar results were also observed when other ROS inhibitors, such as (2R, 4R)-4-
aminopyrrolidine-2,4-dicarboxylate (APDC) or N-acetyl-cysteine (NAC), were used 
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(data not shown). Taken together, these data indicate that mitochondrial ROS production 
is essential for NLRP3 inflammasome activation by charged liposomes and that the 
failure of neutral liposomes to activate the NLRP3 inflammasome directly correlates with 
their inability to induce mitochondrial ROS. 
 
 
 
 
Figure 4.15: Charged but not neutral liposomes induce mitochondrial ROS 
production. Mitochondrial ROS production was measured by flow cytometry in LPS-
primed BMDMs that were stimulated with indicated liposomes (30 µg/ml) and labeled 
with MitoSOX. Data are shown as mean ± s.d., and are representative of at least three 
independent experiments.  
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Figure 4.16: Inhibition of mitochondrial ROS abolishes liposome-induced 
inflammasome activation. (a) LPS-primed wild-type BMDMs were pretreated with DPI 
for 30 min and then stimulated with indicated liposomes (30 µg/ml) for 6 h. The cells 
were then stained with MitoSOX and the levels of mitochondrial ROS were normalized 
to the untreated controls (n=3).  (b) ELISA for IL-1β from the supernatants of LPS-
primed (18 h) BMDMs that were pretreated with DPI before stimulation with indicated 
liposomes (30 µg/ml) or poly(dA:dT) (2 µg/ml). Data are shown as mean ± s.d., and the 
data are representative of three (a) and four (b) independent experiments. 
 
 
 
 
 
 
Figure 4.17: DPI treatment does not affect Il1b and Nlrp3 mRNAs after prolonged 
LPS priming. The mRNA levels of Il1b (left) and Nlrp3 (right) were quantified by real-
time RT-PCR in wild-type BMDMs that were stimulated as indicated. DPI (25 µM) was 
added after 18 h LPS priming but 45min before addition of liposomes. Gene expression 
data are presented as relative expression to HPRT1, and the gene relative expression level 
in 24 h LPS treated wild-type macrophages (DMSO group) were designated as 1. Data 
are representative of three independent experiments. 
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Figure 4.18: Inhibition of NADPH oxidase does not affect liposome-induced IL-1β 
secretion. The levels of IL-1β were measured by ELISA from supernatants of LPS-
primed wild-type BMDMs that were pretreated with VAS2870 for 30 min followed by 
stimulations with DOTAP or DPPC-DMPG liposomes (30 µg/ml) for 6 h. Data are 
shown as mean ± s.d., and are representative of three independent experiments. 
 
 
 
AIM3: DELINEATE WHETHER TRPM2 IS CRITICAL FOR ACTIVATION OF 
THE NLRP3 INFLAMMASOME IN RESPONSE TO PARTICLES 
STIMULATION 
 
Particulates (e.g. liposomes and crystals) induce a ROS-dependent Ca2+ influx via 
the TRPM2 channel  
Our findings indicated that, similar to crystals(Tschopp and Schroder, 2010), 
liposomes activate the NLRP3 inflammasome via the induction of mitochondrial ROS. 
However, little is known about the mechanism by which ROS promote NLRP3 
inflammasome activation. Due to the existence of a diverse pool of stimuli(Gross et al., 
2011), these agonists may activate a common signaling intermediate that directs assembly 
of the NLRP3 inflammasome. Recently, it has been shown that accumulation of ROS can 
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induce a calcium influx via the TRPM2 (transient receptor potential melastatin 2) 
channel(Hecquet and Malik, 2009; Yamamoto et al., 2008). TRPM2 is expressed by 
immune cells, such as dendritic cells, monocytes, macrophages, PMNs and lymphocytes, 
and is a calcium-permeable nonselective cation channel that plays a crucial role in innate 
immune regulation(Sumoza-Toledo and Penner, 2011). TRPM2-mediated calcium influx 
has been implicated in ROS-induced chemokine production in monocytes(Yamamoto et 
al., 2008). Notably, TRPM2-deficient mice are also susceptible to infection of Listeria 
monocytogenes(Knowles et al., 2011), a known activator of the NLRP3 
inflammasome(Kim et al., 2010; Mariathasan et al., 2006). Because calcium appears to 
be a key mediator of various signaling events under stressed conditions, we hypothesize 
that liposomes/crystals induce ROS-dependent TRPM2-medidated calcium influx, which 
eventually signals assembly and activation of the NLRP3 inflammasome. 
As shown in Figure 4.19, we first observed that charged liposomes or crystals 
induced the increase in the concentration of intracellular free calcium ([Ca2+]i). This 
elevation in [Ca2+]i was due to calcium influx across the plasma membrane because the 
removal of extracellular calcium from the buffer solution dramatically inhibited the 
increase of [Ca2+]i (Figure 4.20 and Figure 4.21). Furthermore, blockade of 
mitochondrial ROS by DPI also prevented liposome/crystal-induced calcium influx, 
suggesting that calcium influx is ROS-dependent. Notably, BMDMs deficient in TRPM2 
had similar defects in calcium influx after liposome/crystal stimulation, indicating that 
calcium influx is mediated by the TRPM2 channel (Figure 4.20 and Figure 4.21). To 
further verify the role of TRPM2 in mediating calcium influx, we tested whether 
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inhibition of TRPM2 activation affected liposome/crystal-induced calcium influx. 
TRPM2 channel can be gated by ADP-ribose, a metabolic product formed during cellular 
exposure to ROS(Knowles et al., 2011; Sumoza-Toledo and Penner, 2011). Therefore, we 
treated LPS-primed wild-type BMDMs with DPQ, an inhibitor of poly(ADP-ribose) 
polymerase, to prevent ADP-ribose accumulation(Fonfria et al., 2004; Suto et al., 1991) 
before the addition of liposomes/crystals to determine whether the calcium influx was 
affected. As expected, DPQ significantly reduced calcium influx in response to 
stimulation with particles (Figure 4.20 and Figure 4.21). These data collectively indicate 
that stimulation of macrophages with either liposomes or crystals can trigger ROS-
dependent TRPM2-mediated calcium influx. 
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Figure 4.19: Charged liposomes and crystals induce cytosolic calcium elevation. (a) 
The change in [Ca2+]i over time was represented by the fluorescence of Fura-2 at 340 nm 
to that at 380 nm (F340/F380) and (b) the maximum [Ca2+]i elevations, represented by 
ΔF340/F380, are shown in LPS-primed wild-type BMDMs treated with medium alone, 
cationic liposomes (DOTAP, 30 µg/ml), neutral liposomes (DOPC, 30 µg/ml), anionic 
liposomes (DPPC-DMPG, 30 µg/ml) or silica crystals (300 µg/ml). The data are 
representative of at least three independent experiments and are shown as mean ± s.e.m. 
in b (n=22-31).  
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Figure 4.20: Charged liposomes and crystals induce a ROS-dependent TRPM2-
mediated calcium influx. (a) The time-dependent change in [Ca2+]i, represented by 
F340/F380, in the LPS-primed Trpm2+/+ BMDMs cultured in calcium-containing solution 
that were pretreated with DPI (25 µM) or DPQ (200 µM) for 45min before the addition 
of the indicated liposomes (30 µg/ml) or crystals (alum, 400 µg/ml; silica, 300 µg/ml) is 
shown. The same doses of liposomes or crystals were also used to stimulate the LPS-
primed Trpm2−/− BMDMs cultured in calcium-containing solution. The [Ca2+]i change 
over time, represented by F340/F380, after stimulation with liposomes or crystals in LPS-
primed Trpm2+/+ BMDMs cultured in calcium-free 0.5 mM EGTA-containing solution is 
also shown. Inflammasome agonists were added 1 min after the initiation of calcium 
recording as shown in a. (b) The maximum [Ca2+]i elevations, represented by 
ΔF340/F380, are shown for LPS-primed BMDMs in response to the stimulations 
described in a. The data are representative of at least three independent experiments and 
are shown as mean ± s.e.m. in b (n=21-34).  
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Figure 4.21: MSU crystals induce a TRPM2-mediated Ca2+ influx in macrophages. 
(a) Time-dependent change of [Ca2+]i, represented by F340/F380, was shown in LPS-
primed Trpm2+/+ BMDMs cultured in calcium-containing solution that were pretreated 
with DPI (25 µM) or DPQ (200 µM) for 45min for before the addition of MSU crystals 
(250 µg/ml). The same doses of MSU crystals were used to stimulate the LPS-primed 
Trpm2−/− BMDMs cultured in calcium-containing solution.  The [Ca2+]i over time after 
additions of these stimuli into LPS-primed Trpm2+/+ BMDMs cultured in calcium-free 
0.5 mM EGTA-containing solution are also shown. MSU crystals were added 1 min after 
the starting of calcium recording. (b) The maximum [Ca2+]i elevations, represented by 
ΔF340/F380, were shown in LPS-primed BMDMs in response to the stimulations 
described in a. Data are representative of two independent experiments and are shown as 
mean ± s.e.m. in b (n=21-38). 
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TRPM2-mediated Ca2+ influx regulates particle-induced IL-1β secretion 
We next determined whether TRPM2-mediated calcium influx was critical for IL-
1β release. Trpm2−/− BMDMs demonstrated significantly reduced IL-1β secretion in 
responses to stimulation with the liposomes DOTAP and DPPC-DMPG or the crystals of 
alum, silica and MSU. In contrast, poly(dA:dT)-induced IL-1β secretion, which is AIM2 
inflammasome-dependent(Fernandes-Alnemri et al., 2009; Hornung et al., 2009), was 
largely unaffected (Figure 4.22). Similarly, the removal of extracellular calcium from the 
culture medium significantly impaired the particulate agonist-, but not poly(dA:dT)-, 
induced IL-1β release (Figure 4.22).  
 
 
 
 
Figure 4.22: TRPM2-mediated Ca2+ influx regulates IL-1β secretion. ELISA for IL-
1β from the supernatants of LPS-primed wild-type (Trpm2+/+) or Trpm2−/− BMDMs that 
were stimulated with indicated liposomes (30 µg/ml), crystals (alum, 250 µg/ml; silica 
and MSU crystals, 200 µg/ml) or poly(dA:dT) (2 µg/ml) for 6 h in calcium-containing or 
calcium-free medium. All data are representative of at least three independent 
experiments, and are shown as mean ± s.d.. *, p < 0.05, and **, p<0.01 versus controls. 
Statistical significance was determined by the standard two-tailed Student’s t-test. 
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Furthermore, we observed that the decrease in the mature IL-1β secretion in 
Trpm2−/− BMDMs was not due to the reduction in either pro-IL-1β or NLRP3 levels, the 
genes for which are regulated by NF-κB(Bauernfeind et al., 2009; Gross et al., 2011) 
because TRPM2 deficiency affected neither pro-IL-1β nor NLRP3 (Figure 4.23 and data 
not shown). Consistent with this finding, TNF secretion was not affected by TRPM2 
deficiency (Figure 4.24). Moreover, the inhibition of TRPM2 activation by DPQ also 
significantly impaired liposome-/crystal-, but not poly(dA:dT)-, induced IL-1β secretion 
(Figure 4.25). In contrast to the wild-type cells, Trpm2−/− BMDMs did not display any 
further reduction in IL-1β secretion after DPQ treatment (Figure 4.26), indicating that 
DPQ treatment specifically blocked TRPM2-mediated IL-1β release. It has been shown 
that the inhibition of key enzymes in the mitochondrial respiratory chain can artificially 
increase the levels of mitochondrial ROS and trigger spontaneous NLRP3 inflammasome 
activation in the absence of inflammasome stimuli(Zhou et al., 2011), therefore we next 
verified the role of TRPM2 in mediating IL-1β release under these conditions. To do so, 
we artificially induced the accumulation of mitochondrial ROS with antimycin A, an 
inhibitor that specifically blocks the respiratory chain complex III, and determined 
whether TRPM2 deficiency affected antimycin A-induced IL-1β release. Indeed, we 
found that Trpm2−/− BMDMs had significantly reduced secretion of IL-1β, but not TNF 
(Figure 4.27). Consistently, TRPM2 deficiency also decreased IL-1β secretion in 
response to direct stimulation with ROS, such as H2O2 (Figure 4.27). Together, these 
results suggest a critical role for TRPM2-mediated calcium influx in bioactive IL-1β 
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release, and demonstrate that TRPM2 deficiency specifically impairs the processing of 
immature pro-IL-1β into its mature form. 
It should be noted that in addition to TRPM2-dependent IL-1β release, 
liposomes/crystals also induced TRPM2-independent IL-1β secretion. This effect was 
most likely mediated by ER-calcium release via IP3R, as suggested in a recent study by 
Murakami et al.(Murakami et al., 2012). In support of the hypothesis that calcium influx 
and ER calcium release are both essential for NLRP3 inflammasome activation, we 
observed that the intracellular calcium chelator BAPTA-AM, which blocks [Ca2+]i 
elevation regardless of the source of calcium, almost completely inhibited IL-1β release 
(Figure 4.28) whereas the inhibition of either calcium influx or intracellular ER calcium 
release(Murakami et al., 2012) only partially reduced IL-1β secretion. Together, these 
results demonstrate that both calcium influx and ER calcium release are critical for 
activation of the NLRP3 inflammasome. 
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Figure 4.23: TRPM2 deficiency does not affect the levels of pro-IL-1β. (a) The levels 
of pro-IL-1β mRNA were quantified by real-time RT-PCR in LPS-primed Trpm2+/+ or 
Trpm2−/− BMDMs after stimulation with indicated liposomes and crystals. The gene 
expression data are presented as expression relative to HPRT1, and the relative gene 
expression levels in wild-type macrophages were designated as 1. (b) Immunoblots for 
pro-IL-1β and β-actin in the cell lysates from LPS-primed Trpm2+/+ or Trpm2−/− BMDMs 
after stimulation with liposomes or crystals. All data are representative of at least three 
independent experiments, and are shown as mean ± s.d. in a. 
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Figure 4.24: TRPM2 deficiency does not affect TNF secretion. ELISA TNF from the 
supernatants of LPS-primed wild-type (Trpm2+/+) or Trpm2−/− BMDMs that were 
stimulated with indicated liposomes (30 µg/ml) or crystals (alum, 250 µg/ml; silica and 
MSU crystals, 200 µg/ml) for 6 h in calcium-containing medium. All data are 
representative of at least three independent experiments, and are shown as mean ± s.d.. 
 
 
 
 
 
Figure 4.25: Inhibition of TRPM2 by DPQ significantly impairs liposome-induced 
IL-1β secretion. IL-1β from the supernatants of LPS-primed wild-type BMDMs that 
were pretreated with DPQ (200 µM) followed by inflammasome agonist stimulation All 
data are representative of at least three independent experiments, and are shown as mean 
± s.d.. 
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Figure 4.26: DPQ does not further reduce particles-induced IL-1β release in 
Trpm2−/− BMDMs. ELISA for IL-1β from supernatants of LPS-primed Trpm2−/− 
BMDMs that were pretreated with DPQ (200 µM) followed by stimulations with 
indicated liposomes or crystals. Data are shown as mean ± s.d., and are representative of 
three independent experiments. 
 
 
 
 
 
Figure 4.27: TRPM2 deficiency impairs ROS-induced IL-1β secretion . IL-1β (left) 
or TNF (right) from the supernatants of LPS-primed wild-type BMDMs that were 
stimulated with antimycin A (20 µg/ml) or H2O2 (10 mM) for 6 h. All data are 
representative of at least three independent experiments, and are shown as mean ± s.d.. *, 
p < 0.05, and **, p<0.01 versus controls. Statistical significance was determined by the 
standard two-tailed Student’s t-test. 
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Figure 4.28: Blocking [Ca2+]i elevation abolishes the NLRP3 inflammasome 
activation by particulates. ELISA for IL-1β (a) or TNF (b) from supernatants of LPS-
primed wild-type BMDMs that were pretreated with BAPTA-AM (25 µM) followed by 
stimulations with liposomes or crystals. Data are shown as mean ± s.d., and are 
representative of three independent experiments. 
 
 
 
TRPM2 is critical for particle-induced, NLRP3-mediated caspase-1 activation 
To determine the mechanism by which TRPM2 deficiency leads to impaired 
processing of bioactive IL-1β, we tested whether Trpm2−/− BMDMs were defective in 
caspase-1 activation. As shown in Figure 4.29, deficiency in TRPM2 or the blockade of 
[Ca2+]i increase via BAPTA-AM drastically reduced the level of mature caspase-1 in 
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response to liposomes or crystals. This defect was not due to impaired mitochondrial 
ROS production because neither genetic ablation of TRPM2 nor removal of extracellular 
calcium impaired mitochondrial ROS production after liposome stimulation (Figure 4.30 
and Figure 4.31). Moreover, we found that Nlrp3−/− macrophages displayed a 
comparable level of calcium influx as wild-type cells in response to liposome stimulation 
(Figure 4.32), suggesting that TRPM2-mediated calcium influx is an early event before 
assembly of the NLRP3 inflammasome. Together, these data indicate that ROS-
dependent calcium influx via the TRPM2 channel is critical for NLRP3 inflammasome-
mediated caspase-1 activation. 
 
 
 
 
Figure 4.29: Blocking [Ca2+]i elevation or inhibiting TRPM2 impairs caspase-1 
activation by particulates. (a) Immunoblots of procaspase-1 in lysates and caspase-1 
p10 in culture supernatants of LPS-primed Trpm2+/+ and Trpm2−/− BMDMs that were 
stimulated with indicated liposomes (30 µg/ml) or crystals (250 µg/ml). (b) Immunoblots 
of procaspase-1 and caspase-1 p10 in LPS-primed wild-type BMDMs that were preteated 
with either BAPTA-AM (25 µM) or DMSO before stimulation with the indicated 
liposomes (50 µg/ml) and crystals (400 µg/ml). One of three independent experiments is 
shown in a and b. 
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Figure 4.30: TRPM2 deficiency does not affect liposome-induced mitochondrial 
ROS production. (a-c) LPS-primed Trpm2+/+ or Trpm2−/− BMDMs were treated with 
indicated liposomes (30 µg/ml) for 6 h. The cells were then stained with MitoSOX and 
the levels of mitochondrial ROS were measured by flow cytometry (a, b). The data are 
representative for three experiments and are normalized to the untreated controls (c, n=3). 
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Figure 4.31: Removal of extracellular calcium does not impair mitochondrial ROS 
production. LPS-primed wild-type BMDMs were treated with indicated liposomes (30 
µg/ml) for 6 h in the presence of calcium containing or calcium free medium. Then the 
cells were stained with MitoSOX and the levels mitochondrial ROS were measured by 
flow cytometry. Data are representative for two independent experiments and are 
normalized to untreated controls (n=3). 
 
 
 
 
 
 
Figure 4.32: Calcium influx is an early event before the assembly of NLRP3 
inflammasome. The maximum [Ca2+]i elevations, represented by ΔF340/F380, are 
shown for LPS-primed immortalized murine wild-type or Nlrp3−/− macrophages in 
response to stimulation with liposomes (70 µg/ml). The data are shown as mean ± s.e.m. 
(n=23-28), and are representative of two independent experiments. 
 
 
 
Along with the role of calcium influx in activation of the NLRP3 inflammasome, 
potassium efflux has been shown to be essential for inflammasome activation by most, if 
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not all, NLRP3 inflammasome agonists(Jin and Flavell, 2010; Tschopp and Schroder, 
2010). It appears that the mobilization of both cations across the plasma membrane is 
crucial for NLRP3 inflammasome activation. Consistent with a recent study(Gross et al., 
2012), we found that the blockade of potassium efflux did not prevent calcium influx 
induced by NLRP3 inflammasome agonists (Figure 4.33), which further verifies that in 
addition to potassium efflux, calcium influx is also a crucial event for NLRP3 
inflammasome activation. Because TRPM2 is a non-selective cation channel that allows 
the passage of both calcium and potassium(Sumoza-Toledo and Penner, 2011), it is 
possible that TRPM2 deficiency may also affect potassium efflux. However, as the 
removal of extracellular calcium did not further decrease the particulate-induced NLRP3 
inflammasome activation in Trpm2−/− BMDMs (Figure 4.22), the defect of NLRP3 
inflammasome activation in TRPM2-deficient cells is most likely due to impaired 
calcium influx. 
It should be noted that ATP-induced NLRP3 inflammasome activation was also 
primarily dependent on calcium influx (Figure 4.34). However, in contrast to particulate 
agonists of the NLRP3 inflammasome, ATP uses P2X7, but not TRPM2, to induce 
calcium influx and NLRP3 inflammasome activation (Figure 4.34). Consistent with this 
notion, deficiency in P2X7 did not affect calcium influx triggered by particulate stimuli 
(Figure 4.35). Taken together, these results suggest that calcium influx is a general 
proximal step during NLRP3 inflammasome activation, and that different activators of 
the NLRP3 inflammasome may use distinct plasma membrane ion channels to mediate 
calcium influx. 
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Figure 4.33: Blocking potassium efflux does not affect calcium influx. The maximum 
[Ca2+]i elevations, represented by ΔF340/F380, are shown for LPS-primed immortalized 
murine wild-type or Nlrp3−/− macrophages in response to stimulation with liposomes (70 
µg/ml). The data are shown as mean ± s.e.m. (n=23-28), and are representative of two 
independent experiments. 
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Figure 4.34: ATP activates the NLRP3 inflammasome by inducing Ca2+ influx via 
P2X7 channel. Time-dependent change of [Ca2+]i, represented by F340/F380, was shown 
in LPS-primed Trpm2+/+ and Trpm2−/− BMDMs (a, left pannel) or P2X7+/+ and P2X7−/− 
BMDMs (b, left pannel) cultured in Ca2+-containing solution that were stimulated with 
ATP (2 mM). The calcium flux over time after ATP stimulation in LPS-primed Trpm2+/+ 
BMDMs cultured in calcium-free 0.5 mM EGTA-containing solution was also shown. 
The maximum [Ca2+]i elevations (right panels of a and b), represented by ΔF340/F380, 
were shown in in LPS-primed BMDMs in response to the ATP stimulation. ATP was 
  
74 
added 1 min after the starting of calcium recording. Data are representative of four 
independent experiments and are shown as mean ± s.e.m. in a (n=20-36) and b (n=22-
28). (c) ELISA for IL-1β from supernatants of LPS-primed P2X7−/− or wild-type (P2X7+/+) 
BMDMs that were pretreated with BAPTA-AM (25 µM) followed by stimulations with 
ATP. (d) IL-1β from supernatants of LPS-primed Trpm2+/+ or Trpm2−/− BMDMs that 
were treated with ATP. (e) IL-1β from supernatants of LPS-primed wild-type BMDMs 
that were stimulated with ATP in calcium-containing or calcium-free medium. Data are 
shown as mean ± s.d. in c-e, and are representative of three independent experiments. 
 
 
 
 
 
 
Figure 4.35: Deficiency in P2X7 does not affect liposome-induced [Ca2+]i elevation. 
(a) Time-dependent change of [Ca2+]i, represented by F340/F380, was shown in LPS-
primed P2X7+/+ and P2X7−/− BMDMs cultured in calcium-containing solution that were 
stimulated with DOTAP liposomes (30 µg/ml). DOTAP liposomes were added 1 min 
after the starting of calcium recording. (b) The maximum [Ca2+]i elevations, represented 
by ΔF340/F380, were shown in LPS-primed BMDMs in response to the stimulation as 
described in a. Data are representative of two independent experiments, and are shown as 
mean ± s.e.m. in b (n=25-36). 
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TRPM2 is crucial for NLRP3 inflammasome activation in vivo 
To further validate the role of TRPM2 in mediating NLRP3 inflammasome 
activation in vivo, we determined whether TRPM2 deficiency affected crystal-/liposome-
induced IL-1β secretion and subsequent neutrophil recruitment after intraperitoneal 
injections of these particulate stimuli. We first observed that the level of IL-1β in the 
peritoneal fluid of the Trpm2−/− mice was significantly reduced as compared to that from 
wild-type mice after injection with either MSU crystals or DOTAP liposomes (Figure 
4.36). Moreover, particle-induced neutrophil recruitment was also significantly decreased 
in Trpm2−/− mice, which was similar to that observed in Il1rl−/− mice (Figure 4.37). In 
contrast, neutrophil recruitment was not affected by either TRPM2 or IL-1R deficiency in 
response to an intraperitoneal challenge with zymosan, a Toll-like receptor 2 agonist 
(Figure 4.38). These data collectively indicate that TRPM2 is essential for NLRP3 
inflammasome activation in vivo. 
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Figure 4.36: TRPM2 is critical for particle-induced IL-1β release in vivo. The IL-1β 
concentration (a, b) were quantified in peritoneal lavage fluid from wild-type (Trpm2+/+), 
or Trpm2−/− mice 6 h after intraperitoneal injection of PBS supplemented with either 
MSU crystals (a) or DOTAP liposomes (b). The data are representative of two 
independent experiments (mean and s.e.m. of three to five mice per group). *, p<0.05 
versus controls. Statistical significance was determined by the standard two-tailed 
Student’s t-test. 
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Figure 4.37: TRPM2 and IL-1R mediate particle-induced peritonitis. The neutrophil 
recruitment (a-d) were quantified in peritoneal lavage fluid from wild-type (Il1rl+/+ and 
Trpm2+/+), Il1rI−/− or Trpm2−/− mice 6 h after intraperitoneal injection of PBS 
supplemented with either MSU crystals (a, c) or DOTAP liposomes (c, d). The data are 
representative of two independent experiments (mean and s.e.m. of three to five mice per 
group). *, p<0.05 versus controls. Statistical significance was determined by the standard 
two-tailed Student’s t-test. 
 
 
 
  
78 
 
 
 
Figure 4.38: Deficiency in TRPM2 or IL-1R does not affect zymosan-induced 
peritonitis. IL-1β concentrations (a) and neutrophils influx (b) were quantified in 
peritoneal lavage fluid from wild-type (Il1rl+/+ or Trpm2+/+), Il1rI−/− or Trpm2−/− mice 6h 
after intraperitoneal injection of PBS (0.5 ml) supplemented with zymosan (0.2 mg). Data 
are representative of two independent experiments (mean and s.e.m. of five mice per 
group). 
 
 
 
TRPM2 is crucial for the adjuvant effect of liposomes in vivo 
Finally, we tested whether deficiency in TRPM2, which results in decreased IL-
1β secretion, would affect the adjuvanticity of liposomes in vivo. As shown in Figure 
4.39, the level of ovalbumin (OVA)-specific IgG1 was significantly reduced in Trpm2−/− 
mice after immunization with OVA-encapsulated DOTAP liposomes. However, in 
contrast to the liposomal adjuvant, a deficiency in either TRPM2 did not impair the 
optimal levels of anti-OVA antibodies when LPS, a Toll-like receptor 4 agonist, was used 
as the adjuvant (Figure 4.39), which suggests that TRPM2- and IL-1R-deficient mice do 
not have a general defect in mounting an antibody response. Taken together, these data 
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indicate that TRPM2 and IL-1R are essential for the induction of an optimal antibody 
response against the antigens that are encapsulated within liposomes. 
 
 
 
Figure 4.38: TRPM2 is critical for liposome’s adjuvanticity. Six- to eight-week old 
female wild-type (Trpm2+/+) or Trpm2−/−  mice were subcutaneously immunized on day 0 
and day 14 with 40 µg/mouse ovalbumin (OVA) alone or the same amount of OVA 
encapsulated within DOTAP liposomes (a) or mixed with LPS (25 µg/mouse, b). On day 
24, the mice were sacrificed, and sera were collected and analyzed for OVA-specific 
IgG1, IgG2b, and IgG2c levels by ELISA. The data are shown as geometrical mean ± 
s.e.m., and are representative of at least two independent experiments (n=4-5 mice per 
group). *, p<0.05 versus controls. Statistical significance was determined by the standard 
two-tailed Student’s t-test. 
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CHAPTER 5 
DISCUSSION 
Liposomes are promising immune adjuvants and delivery vectors for the 
treatment of both infectious and cancerous diseases(Allison and Gregoriadis, 1974; 
Christensen et al., 2007; Slingerland et al., 2012). Therefore, understanding the innate 
immune recognition process for liposomes will not only mechanistically define/improve 
their adjuvant effect but also help to prevent any undesirable inflammatory responses, 
particularly when liposomes are used as drug-delivery vehicles for anti-cancer therapies. 
In this thesis study, I identified the NLRP3 inflammasome as a novel innate immune 
sensor for liposomes. Notably, only the charged, but not neutral, liposomes activated the 
NLRP3 inflammasome, which is most likely due to the fundamental differences in their 
induction of mitochondrial ROS. Because the plasma membrane potential is tightly 
associated with the oxidative state in phagocytes(DeCoursey, 2010; DeCoursey et al., 
2003; Murphy and DeCoursey, 2006), it is plausible that charged, but not neutral, 
liposomes could induce cellular oxidative stress via alteration of the plasma membrane 
potential, which would eventually result in NLRP3 inflammasome activation. Therefore, 
charged liposomes may be more suitable as immune adjuvants, whereas neutral 
liposomes may be more suitable as delivery vectors for anti-cancer drugs. 
We also performed additional experiments to test whether the extent of NLRP3 
inflammasome activation depends upon the dose and size of the liposomes. As expected, 
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charged liposomes induce IL-1β secretion in a dose dependent manner. Interestingly, the 
size of liposome also determined the amount of IL-1β secretion. It seems that, within the 
range of 100nm to 800nm in diameter, the liposome-induced IL-1β secretion displayed a 
liner positive correlation with the size of liposomes.  
To mechanistically understand how liposomes activate the NLRP3 inflammasome, 
we first tested if potassium efflux, a seemingly obligatory event for NLRP3 
inflammasome activation by essentially all its known activators, was required for 
liposome-induced inflammasome activation. Indeed, similar to all other known activators, 
the inhibition of potassium efflux completely abolished NLRP3 inflammasome activation 
by liposomes. We next tested whether the uptake of liposomes is a necessary step for 
NLRP3 inflammasome activation. Indeed, we found that the inhibition of phagocytosis in 
macrophages drastically impaired liposome-induced NLRP3 inflammasome activation. 
This is likely due to that the uptake of liposomes is required to induce a stress signal that 
can be sensed by the intracellular innate immune receptor, NLRP3. Interestingly, 
although the initial phagocytic pathway is required, we found that the lysosome-cathepsin 
B pathway seems dispensable for liposome-induced NLRP3 inflammasome activation 
because the inhibition of lysosome acidification or genetic blockade of cathepsin B 
activity did not significantly affect liposome-induced NLRP3 inflammasome activation. 
This suggests that the signals necessary for directing NLRP3 inflammasome activation by 
liposomes appear to be independent of lysosome-derived contents. 
ROS has been proposed to be a key player that drives NLRP3 inflammasome 
activation by most activators. It has been demonstrated that artificially induction of ROS, 
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in the absence of NLRP3 inflammasome agonists, can trigger spontaneous NLRP3 
inflammasome activation and subsequent proinflammatory cytokine secretion. Moreover, 
the blockade of ROS generation from mitochondria by pharmocologica or genetic means 
can strongly inhibit NLRP3 inflammasome activation by a number of stimuli. It appears 
that ROS plays a central role in orchestrating the immune responses by activating the 
NLRP3 inflammasome.  
Although an essential role for mitochondrial ROS has recently been implicated in 
activation of the NLRP3 inflammasome(Kepp et al., 2011; Tschopp, 2011), the precise 
mechanism underlying ROS-induced inflammasome activation remains elusive. In this 
thesis study, I identified a novel signaling axis originating from ROS production, 
followed by TRPM2-mediated calcium influx and ultimately activation of the NLRP3 
inflammasome. Therefore, these findings provide at least one mechanistic link that 
connects oxidative stress with NLRP3 inflammasome activation. Furthermore, the 
identification of TRPM2 as the responsible channel for calcium influx during NLRP3 
inflammasome activation also further advanced our understanding of how calcium 
mobilization occurs upon stimulation with NLRP3 agonists. 
Besides TRPM2, a previous study has also identified TXNIP (thioredoxin-
interacting protein) as another link between oxidative stress and NLRP3 inflammasome 
activation. Upon stimulation with NLRP3 agonists, TXNIP disassociates with its binding 
protein TRX (thioredoxin) which allows the direct binding of TXNIP to NLRP3. 
However, TXNIP does not seem to be a universal regulator of NLRP3 inflammasome 
because several recent studies have shown that TXNIP is dispensable for NLRP3 
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inflammasome activation by other stimuli. Nonetheless, further studies are indeed 
necessary to delineate the possible relationship between TNXIP, TRPM2, and NLRP3 
inflammasome activation. It would be interesting to see if genetic ablation of TXNIP may 
affect TRPM2 mediated calcium influx. Alternatively, calcium mobilization might also 
be a prerequisite for TXNIP to interact and activate NLRP3. 
In addition to TRPM2-dependent IL-1β release, we observed that a portion of 
particle-induced IL-1β secretion was independent of TRPM2-mediated calcium influx but 
instead was dependent on calcium release from intracellular stores. This observation is 
consistent with a recent report by Murakami et al. that demonstrated a role for IP3R-
mediated calcium release from the ER in activation of the NLRP3 
inflammasome(Murakami et al., 2012). Additionally, two recent studies have also 
demonstrated that extracellular calcium elevation, which is a common phenomenon under 
local inflammation when cell’s integrity is compromised, can serve as a danger signal 
which ultimately induces IP3R-mediated calcium release from ER to activate the NLRP3 
inflammasome.  
Although it is clear that both calcium influx and ER calcium release are critical 
for IL-1β secretion, how multiple calcium mobilization events cooperatively trigger 
NLRP3 inflammasome activation remains to be further defined. Recently, a report by 
Zhou et al. demonstrated a close interaction between the ER and mitochondria in 
response to NLRP3 inflammasome stimuli. Because calcium overload in mitochondria is 
essential for ROS production, it is plausible that ER-mitochondria contact may be 
beneficial for rapid calcium flow from the ER into mitochondria, which may facilitate the 
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generation of sufficient mitochondrial ROS, particularly at later stage during activation of 
the NLRP3 inflammasome. Moreover, Murakami et al. have also demonstrated that in 
addition to facilitating mitochondrial ROS production, ER-derived calcium is also 
essential for mitochondria to maintain a damaged state(Murakami et al., 2012). 
Mitochondrial damage has been shown to induce the release of mitochondrial DNA 
(mtDNA) into the cytosol, which also activates the inflammasomes(Nakahira et al., 2011; 
Shimada et al., 2012). In addition to mtDNA, our study demonstrates that ROS released 
from the damaged mitochondria activate the TRPM2 channel, which results in calcium 
influx across the plasma membrane. Because blocking TRPM2-mediated calcium 
mobilization drastically impaired caspase-1 activation and did not affect mitochondrial 
ROS production, it is possible that, unlike ER-derived calcium, TRPM2-mediated 
calcium influx may directly signal activation of the NLRP3 inflammasome.  
Based on our current study and a previous report by Murakami et al.(Murakami et 
al., 2012), it appears that calcium mobilization is a critical step during NLRP3 
inflammasome activation. Calcium is a key signaling mediator for a number of cellular 
proteases, protein kinases and phospholipases, some of which may be involved in NLRP3 
inflammasome activation. Consistent with this notion, ERK1/2 kinase has been 
implicated in regulating activation of the NLRP3 inflammasome(Cruz et al., 2007). 
Similarly, we have preliminary data indicating that the inhibition of protein kinase C α 
also partially impairs NLRP3 inflammasome activation (unpublished results). These 
calcium-dependent enzymes may function to either proteolytically inactivate a negative 
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regulator or activate a positive regulator of NLRP3, resulting in the assembly of the 
inflammasome complex. 
Finally, accumulating evidence has suggested that dysregulation of the NLRP3 
inflammasome is tightly associated with many inflammatory disorders, such as gout, 
atherosclerosis, silicosis, asbestosis, and Alzheimer’s disease(Davis et al., 2011; Strowig 
et al., 2012). In this study, we demonstrated that TRPM2 deficiency drastically impairs 
the inflammatory response induced by MSU crystals, the casual agent of gout. This 
finding has therefore suggested a therapeutic potential of targeting TRPM2 to treat 
NLRP3 inflammasome-associated autoinflammatory diseases. Furthermore, other studies 
have also linked the NLRP3 inflammasome to a number of metabolic diseases, including 
obesity and type 2 diabetes(Stienstra et al., 2010; Vandanmagsar et al., 2011; Wen et al., 
2011). For instance, NLRP3 deficiency protects mice from high-fat diet-induced obesity, 
and the saturated fatty acid palmitate, which is found in high-fat diets, can induce NLRP3 
inflammasome-mediated IL-1β secretion, which interferes with insulin signaling and 
eventually results in reduced glucose tolerance and insulin sensitivity. Because our results 
indicate a role for TRPM2 in NLRP3 inflammasome activation, blocking TRPM2 would 
be expected to rescue metabolic disorders that are a result of a high-fat diet. In support of 
this hypothesis, a recent study suggested that TRPM2-deficient mice have attenuated 
obesity-mediated inflammation and that TRPM2 deletion can protect mice from 
developing diet-induced obesity and insulin resistance(Zhang et al., 2012). Together, 
these studies highlight the therapeutic potential of targeting TRPM2 to treat 
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autoinflammatory and metabolic disorders associated with undesirable activation of the 
NLRP3 inflammasome.  
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